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Over the last 20 years, there has been increasing focus on the development of novel stem cell based
therapies for the treatment of disorders and diseases affecting the enteric nervous system (ENS) of the
gastrointestinal tract (so-called enteric neuropathies). Here, the idea is that ENS progenitor/stem cells
could be transplanted into the gut wall to replace the damaged or absent neurons and glia of the ENS.
This White Paper sets out experts’ views on the commonly used methods and approaches to identify,
isolate, purify, expand and optimize ENS stem cells, transplant them into the bowel, and assess transplant
success, including restoration of gut function. We also highlight obstacles that must be overcome in orderY, PWA and NT are lead authors on Sections 1–9.
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This white paper, authored by 30 members of the enteric nervous
system (ENS) basic science and clinical ﬁeld, sets out their opinions on
efforts to establish novel stem cell therapies for enteric neuropathies
of the gastrointestinal tract. Such enteric neuropathies remain some of
the most challenging clinical disorders to manage. Arguably the best
understood enteric neuropathy is the congenital disorder Hirsch-
sprung disease (HSCR) in which the neural crest-derived intrinsic ENS
is absent in a variable length of the distal gut (called “aganglionosis”).
The only treatment currently available for HSCR is surgical removal of
the aganglionic bowel segment, and although life saving, chronic
gastrointestinal problems, including faecal incontinence and en-
terocolitis, signiﬁcantly reduce the quality of life for many people with
HSCR even after surgery. Due to these problems, a novel treatment,
whereby stem cells are transplanted into the aganglionic segment to
replace the missing ENS, has been proposed and over the last 10–15
years numerous international groups have been, and are currently,
involved in preclinical studies aimed at developing such a cell re-
placement therapy.
To put this work in context, it is important to know that the hu-
man ENS contains approximately 500 million neurons and four times
as many glia distributed along the entire bowel in two interconnected
layers called the submucosal and myenteric plexus (Furness, 2006).
These neurons and glia control bowel motility, respond to sensory
stimuli, regulate blood ﬂow, support epithelial function and modulate
local immunity (Furness, 2012). To perform these roles, there are at
least 14 enteric neuron subtypes (Furness, 2000) that express every
neurotransmitter in the CNS and there are several types of enteric glia.
All cells of the ENS are neural crest-derived and migrate into the
bowel during week three to eight of human gestation (or day 9.5–13.5
of mouse fetal development) and then must differentiate and estab-
lish a sophisticated regulatory network (Sasselli et al., 2012b). The goal
of stem cell therapy is to repair or replace defective or missing enteric
neurons and/or glia to improve bowel function.
At the fourth international meeting “Development of the enteric
nervous system; cells, signals, genes and therapy” held in Rotterdam,
The Netherlands (April 2015), a multidisciplinary group of basic sci-
entists and clinicians, including surgeons, gastroenterologists, and
pathologists, decided that a White Paper should be written to clearly
set out methods and approaches to identify, isolate, purify, expand
and optimize ENS stem cells and progenitors, transplant them into the
bowel, and assess transplant success as a way to restore gut function.
By reviewing published studies on ENS stem cell therapy, we identi-
ﬁed speciﬁc areas to help direct future research, gaps in knowledge,
and strategies to address these challenges, taking advantage of
knowledge gained from central nervous system (CNS) stem cell biol-
ogy. Although there are no “gold standard” approaches to isolate and
propagate ENS stem cells, published studies delineate many methods
commonly used in this ﬁeld. This White Paper aims to form a con-
sensus and provide the ENS and stem cell biology communities with
protocols for working with ENS stem cells, for their transplantation
into the bowel, and for their subsequent analysis.
Considering the steady advance and success of several pre-
clinical trials in animal models, we now need to consider “ﬁrst in
man” studies of stem cell therapy for enteric neuropathies. Here
we also discuss obstacles that must be overcome to move ENS
stem cell therapy to the clinic. This includes a discussion of the
“best” diseases to initially treat, the accompanying safety studies
that will need to be performed, and an outline of what “ﬁrst in., White paper on guidelines
.doi.org/10.1016/j.ydbio.2016man” studies should include. With the emergence of new techni-
ques, including approaches to label stem cells for transplantation
and new gene editing technology, we are optimistic that ENS stem
cells, capable of reforming enteric neuronal networks, will be
obtained more reproducibly and with higher efﬁciency in near
future. Here we aim to deﬁne standard methodologies that can be
adapted to provide the necessary safety, regulatory and good
manufacturing practice protocols required for eventual clinical
application.1. What are the target diseases for stem cell transplantation?
Neurogastrointestinal diseases are congenital or acquired dis-
orders that affect the GI tract focally or diffusely and may involve
all enteric neurons or only a subpopulation. Etiologies for neu-
rointestinal diseases include genetic, inﬂammatory, degenerative,
or paraneoplastic processes. Given this complexity, one needs to
consider the underlying defect and its etiology in choosing the
most reasonable targets for cell transplantation in animal models
and, ultimately, for human clinical trials. Here we describe the
pathophysiology of several neurogastrointestinal diseases that
represent promising targets for cell-based therapy.
1.1. Hirschsprung disease (HSCR)
HSCR results from failure of enteric neural crest-derived cells to
complete colonization of the distal intestine during fetal development.
The uncolonized distal bowel remains aganglionic and tonically con-
tracted, causing functional obstruction. Short-segment HSCR, in which
the rectosigmoid colon lacks ganglion cells, affects 80% of patients,
while the remainder have more extensive aganglionosis proximal to
the rectosigmoid. Current treatment involves surgical removal of the
aganglionic segment, but functional outcome is variable and many
patients suffer life-long complications (Conway et al., 2007; Laughlin
et al., 2012; Ludman et al., 2002; Pini Prato et al., 2008; Tsuji et al.,
1999). This may reﬂect dysfunction of the so-called “normo-gang-
lionic” segment (Di Lorenzo et al., 2000; Kohno et al., 2007), abnormal
anal sphincter function, retention of aganglionic distal bowel, or the
sequelae of proctectomy. Enteric neuronal stem/progenitor cell (ENSC)
transplantation provides a potential therapy to replace absent ganglia.
For this purpose, ENSCs have been successfully isolated from gang-
lionic and aganglionic bowel of human HSCR patients and expanded
in culture. These cells migrate and differentiate into neurons and glia
following transplantation into embryonic hindgut (Almond et al.,
2007; Metzger et al., 2009b; Wilkinson et al., 2015). Furthermore,
studies using murine ENSCs from embryonic and postnatal intestine
showed that transplanted ENSCs differentiate into neurons with pro-
cesses that project into the gut muscle and form functional, synaptic
connections (Hotta et al., 2013).
Identifying the optimal source of ENSCs for transplantation is a
priority (discussed in Section 3). For clinical application, autologous
cells avoid the issue of immunologic rejection. HLA-matched human
embryonic stem cells or patient-speciﬁc induced pluripotent stem
(iPS) cells also represent potential sources, but driving them along the
correct lineage to generate functional enteric neurons and, if neces-
sary, “correcting” the inherited genetic mutation present in those cells,
remain major challenges. Choosing the right animal model of agan-
glionosis to test cell-based therapy is also important (discussed in
Section 2). Models used to date include benzalkonium chloride (BAC)-concerning enteric nervous system stem cell therapy for enteric
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as Endrb-deﬁcient (Gariepy et al., 1996) and Sox 10-deﬁcient (Mar-
tucciello et al., 2007) rodents. These studies indicate that grafted cells
can survive and migrate in the absence of an endogenous ENS, but
whether they generate functioning neuronal networks in a postnatal
host remains unclear. Efforts have been made to improve cell labelling
to track transplanted cells (Natarajan et al., 2014) and to optimize cell
delivery methods, laying the foundation for clinical application. Ulti-
mately, however, demonstrating that transplanted ENSCs can ame-
liorate the motility defect present in animals models of HSCR must be
accomplished before considering human application.
1.2. Esophageal achalasia
Loss of nitric oxide synthase (NOS)-expressing nitrergic neurons
causes enteric dysmotility, including esophageal achalasia, where in-
sufﬁcient nitrergic neurons at the lower esophageal sphincter (LES)
impairs its ability to relax, leading to a functional obstruction, dys-
phagia, and regurgitation (Vaezi, 2013). Current treatments target the
LES using pharmacological therapy with nitrates or calcium channel
blockers, physical disruption by pneumatic dilation, or surgical divi-
sion (myotomy). These approaches all have a risk of complications,
failure of symptom resolution, or disease recurrence. The hypothesis
that LES dysfunction results from unbalanced stimulation by choli-
nergic nerves led to the use of botulinum toxin, a potent inhibitor of
acetylcholine release. While botulinum toxin provides transient
symptom relief, it is not a long-term cure (Boeckxstaens, 2006).
Theoretically, the most physiological approach to treatment of acha-
lasia lies in restoring the inhibitory, mainly nitrergic, elements of the
myenteric plexus, which could be accomplished by transplantation of
neuronal precursors to replace the missing population. Achalasia has
been proposed to be an ideal target for ENSC transplantation (Schafer
et al., 2009) for a number of reasons: (1) the neural deﬁcit is well
deﬁned, (2) the target area (LES) is localized and small, and (3) neural
precursors can be delivered endoscopically. However, signiﬁcant
challenges remain, including identifying the best source of re-
generative cells, developing methods to grow large numbers of ENSCs
in vitro prior to transplantation, and establishing methods to direct
neuronal phenotype toward NOS expression.
1.3. Gastroparesis
Gastroparesis, characterized by delayed emptying of food from the
stomach, is diagnosed clinically, based on nuclear medicine imaging
tests or breath testing. A stomach biopsy is not typically performed.
Thus, although neuromuscular abnormalities have long been sus-
pected in idiopathic and diabetic gastroparesis, this has only recently
been conﬁrmed. Loss of interstitial cells of Cajal (ICC) and decreased
neuronal nitric oxide synthase (nNOS) expressing cells are the most
commonly identiﬁed abnormalities in the stomach of people with
gastroparesis (Grover et al., 2011). The effect of injecting neural stem
cells into the pylorus to induce muscle relaxation and accelerate
gastric emptying has been tested using nNOS-deﬁcient mice that are
an established model of gastroparesis. Although grafted cells survived
only one week, transplanted mice demonstrated improved gastric
emptying (Micci et al., 2005). While not all patients with gastroparesis
have loss or dysfunction of nNOS-expressing cells, these results sug-
gest that ENSC therapy may beneﬁt those individuals that do. Un-
fortunately, there is not a clear clinical correlation between improved
gastric emptying and symptoms in people with gastroparesis, as
gastric accommodation and sensory function may also be altered, so
an additional question is whether this therapy will enhance quality of
life even if gastric emptying improves.Please cite this article as: Burns, A.J., et al., White paper on guidelines
neuropathies. Dev. Biol. (2016), http://dx.doi.org/10.1016/j.ydbio.20161.4. Hypertrophic pyloric stenosis
Infantile hypertrophic pyloric stenosis (IHPS) occurs in 1–3 per
1000 children, usually 1 month-old males, and is characterized by
pyloric muscle hypertrophy, resulting in luminal occlusion that leads
to projectile vomiting, weight loss, and dehydration (Mitchell and
Risch,1993; Peeters et al., 2012). Surgical division of the pyloric muscle
(pyloromyotomy) is an effective treatment, but subjects an infant to
abdominal surgery. IHPS is hypothesized to be due to a marked re-
duction in the number of inhibitory nNOS ﬁbers in the hypertrophied
muscle (Vanderwinden et al., 1992). If this mechanism is correct, then
ENSC transplantation might be an effective therapy that could be
delivered endoscopically and without surgery. In support of this hy-
pothesis, mice with targeted disruption of the nNOS gene demon-
strate enlarged stomachs and gastric outlet obstruction due to pyloric
hypertrophy (Huang et al., 1993). In this model, transplanted neural
stem cells produce nNOS and ameliorate the pyloric obstruction (Micci
et al., 2005). Therefore, cell therapy for IHPS may be an achievable
goal, although further analysis is needed to determine how ENSCs
lead to functional improvement and if the improvement is sustained.
One important issue is that IHPS may be clinically and genetically
heterogeneous. In fact, IHPS may be due to defects in ICC or smooth
muscle components (Peeters et al., 2012). Environmental factors have
also been proposed as potential causes, including erythromycin ex-
posure (Honein et al., 1999), feeding practice (Krogh et al., 2012), and
cholesterol levels (Feenstra et al., 2013). Proper patient selection is
critical for cell therapy success, since IHPS due to reduced nNOS-ex-
pressing neurons is much more likely to respond to ENSC transplan-
tation than IHPS due to a primary myopathy or ICC defect.
1.5. Chronic intestinal pseudo-obstruction (CIPO)
CIPO is a clinical diagnosis describing patients with symptoms of
small bowel obstruction and dilated intestine in the absence of me-
chanical blockage or aganglionosis. Occurring in about 1 in 40,000
live-births (Vargas et al., 1988), CIPO is a functional motility disorder of
the small intestine that can have a neuropathic or myopathic cause
(Knowles et al., 2013; Mousa et al., 2002). Although the neuropathy
can have a variety of causes, including developmental, metabolic, in-
ﬂammatory, infectious, and paraneoplastic, the majority of cases in
children are idiopathic and affect the intestine diffusely (Heneyke
et al., 1999). In a small number of pediatric cases, inﬂammation in the
ENS, referred to as enteric ganglionitis (usually affecting the myenteric
plexus), has been observed with lymphocytic (De Giorgio et al., 2002)
or eosinophilic (Schappi et al., 2003) inﬁltrates in the ganglia. Neu-
ronal injury or degeneration leads to intestinal dysmotility. Apart from
small series reporting use of immunomodulators to treat inﬂamma-
tion when this is the underlying cause (De Giorgio and Camilleri,
2004), current treatment is supportive, with the provision of enteral
and parenteral nutrition, and surgery to decompress the intestine.
Few animal models of CIPO exist (Clarke et al., 2007; Fu et al., 2013;
Puig et al., 2009). A transgenic mouse with enteric neuropathy, de-
layed gastrointestinal transit, and selective loss of nNOS-expressing
neurons has been described (Wangler et al., 2014) as well as a model
of disordered ENS network formation and intestinal dysmotility sec-
ondary to mutations in planar cell polarity genes (Sasselli et al., 2013).
Generation of additional models of neuropathic CIPO would facilitate
future studies. Cell therapy could potentially be useful for treating
highly selected cases of CIPO in which an enteric neuropathy is cau-
sative and where ongoing injury to the ENS, such as from para-
neoplastic antibodies or active inﬂammation, is controlled. Since CIPO
is a broad clinical diagnosis, rather than a deﬁnitive pathologic con-
dition, careful evaluation to deﬁne disease etiology prior to trans-
plantation is necessary for successful human therapy. The diffuse
nature of Involvement adds an additional level of complexity in regard
to cell transplantation therapies.concerning enteric nervous system stem cell therapy for enteric
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Neurogenic constipation is a poorly deﬁned condition that affects
adults and children (Longstreth et al., 2006). Common causes include
spina biﬁda and spinal cord injury (both extrinsic to the intestinal
tract) and idiopathic slow transit constipation (intrinsic to the colon).
The etiologies of intrinsic neurogenic constipation remain largely
unknown. There are contradictory neurotransmitter data in pediatric
slow transit constipation (King et al., 2010), with similar controversies
in the adult literature (Walters et al., 2010). It is believed that the
constipation which commonly accompanies human ageing is a result
of age-related enteric neuronal loss (Bernard et al., 2009; El-Salhy
et al., 1999). Animal models exist that may be useful to test the efﬁcacy
of cell therapy for treating neurogenic constipation (Zarate and
Spencer, 2011).
1.7. Chagas disease
Chagas disease is caused by the parasite Trypanosoma cruzi. The
disease is endemic in South and Central America and causes 415,000
deaths annually (Clayton, 2010). Acute symptoms go largely un-
attended and the infection subsides without treatment. However,
some patients develop chronic infection, leading to cardiomyopathy,
mega-esophagus and megacolon (Koberle, 1968) thought to be caused
by massive loss of enteric neurons in affected segments of the gut (da
Silveira et al., 2007; Meneghelli, 2004; Jabari et al., 2014; Ribeiro et al.,
1998). Although animal models exist for Chagasic ENS alterations
(Jelicks, 2010; Nogueira-Paiva et al., 2014; Teixeira et al., 1983), the
potential of ENSC transplantation has yet to be tested.
1.8. Other enteric neuropathies
Gastrointestinal dysmotility has been associated with a wide
variety of putative alterations in the numbers, shapes, and subtypes of
enteric neurons (Knowles et al., 2010). However, apart from the
aforementioned conditions and a few other rare disorders (e.g., neu-
ronal intranuclear inclusion disease), pathogenic connections between
histopathological or immunohistochemical ﬁndings and impaired
motility remain largely speculative. In some instances, conditions
touted as primary neuropathies based on subtle neuropathological
ﬁndings (e.g., megacystic microcolon hypoperistalsis syndrome,
X-linked intestinal pseudo-obstruction) were later shown to be dis-
orders of smooth muscle (Kapur et al., 2010; Wangler et al., 2014).
Many studies have examined neurotransmitter expression in the co-
lon of patients with slow transit constipation, analyzing levels of a
wide array of neurotransmitters, including VIP, NPY, 5-HT, Substance P,
NO, and many others. The results of these studies, summarized pre-
viously (De Giorgio and Camilleri, 2004; Knowles and Martin, 2000)
are highly variable, making it difﬁcult to arrive at any deﬁnitive con-
clusions regarding the role of abnormal neurochemical coding in the
pathophysiology of this condition. Obtaining reliable data in these
studies is often hampered by small numbers of subjects, heterogeneity
of patients, lack of precise criteria for diagnosing types of slow transit
constipation, inconsistencies in tissue source and ﬁxation method,
absence of normative data, and lack of a reliable approach to quan-
titatively measure neurotransmitter amount. Expansion of the po-
tential array of target diseases for ENSC transplantation will depend
on multidisciplinary studies of patients with conservative interpreta-
tion of enteric neuromuscular pathology to establish objective diag-
nostic criteria for new or controversial conditions.
1.9. Phenotyping and genotyping of enteric neuropathies
One favored approach for cell therapy for enteric neuropathies is to
transplant stem cells isolated from a normo-ganglionic region of a
patient’s gut into the affected region thus avoiding immune rejection.Please cite this article as: Burns, A.J., et al., White paper on guidelines
neuropathies. Dev. Biol. (2016), http://dx.doi.org/10.1016/j.ydbio.2016However, in order to do this, it will be important to phenotypically
characterize patients both clinically, to clearly deﬁne the disease type,
as well as pathologically, to inform on the status of the ENS. Further,
genetic characterization of patients will need to be performed to de-
termine whether they have mutations in known genes, whether these
mutations would potentially compromise the ability of ENS stem cells
to reform an ENS, and if so whether the genetic defect could be res-
cued with gene manipulation prior to cell transplant. The importance
of genotyping is also relevant if patient-derived iPS cells are to be used
for cell replacement therapy.
However, genetic characterization of patients with enteric neuro-
pathies could prove problematic, not only due to the genetic com-
plexity of HSCR but also to the lack of genetic understanding of the
majority of other enteric neuropathies in general. For example, based
on familial occurrence, recurrence in siblings, and on the presence of
many naturally occurring animal models with colonic aganglionosis,
HSCR is considered to be an inherited disease. However, the mode of
inheritance can be dominant with reduced penetrance, mostly found
in non-syndromic familial HSCR cases, whereas in families with syn-
dromic HSCR a recessive pattern of inheritance is often observed. The
sporadic cases, which comprise the majority, are considered oligo-
genic or even polygenic (Amiel et al., 2008). Genetic dissection of
HSCR has, to date, implicated mutations in at least 16 genes that can
cause, or contribute to, the development of HSCR, with RET re-
presenting the major HSCR gene (Bergeron et al., 2013). Most of the
other genes have been identiﬁed in rare (familial) syndromic HSCR
cases (Amiel et al., 2008). In addition to the rare, coding mutations
with large effects, common, non-coding variants with small effects
have also been identiﬁed (Emison et al., 2010; Jiang et al., 2015).
While HSCR is the “best understood” enteric neuropathy, its
genetics are indeed complex and much remains to be learned.
Most other enteric neuropathies are arguably even less well
characterized, particularly genetically.
1.10. Conclusion
Achieving success in initial clinical trials of ENSC transplantation
requires that we choose the right target disease. While most animal
studies have focused on HSCR, this represents a high hurdle for clinical
transplantation given the often extensive loss of enteric neurons and
glia, and the associated secondary microenvironmental changes that
create a milieu that may not be permissive to transplanted cells. We
need to improve the characterization of all intestinal neuropathies to
enhance our understanding about what cell types are abnormal, to
determine the extent of the abnormality along the length of the
gastrointestinal tract, and to identify prognostic factors that might
predict which patients could most beneﬁt from cell therapy. Initial
trials should target diseases with focal loss of speciﬁc neuronal sub-
types, as in esophageal achalasia or possibly gastroparesis. Clinical
improvement in those conditions would set the stage for signiﬁcant
advances in the ﬁeld, including optimization of cell isolation and
culture methods and improved strategies for cell engineering and
delivery.2. What are the most appropriate models for experimentation
and treatment of gastrointestinal neuropathies?
For a stem/progenitor cell therapy for gastrointestinal neuro-
pathies, most prominently Hirschsprung Disease (HSCR), a vital sta-
ging-post to a clinical solution is choice of models. What are examples
of the “right kind” of cells for therapy, and what are appropriate
models of the affected bowel?What models and assays can be used to
test cell migration, differentiation, connectivity, and function? Are the
models used relevant for embryonic or post-natal conditions and does
this matter? How does the species being used inﬂuence the results inconcerning enteric nervous system stem cell therapy for enteric
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to answer speciﬁc questions? When should a “step-up” be made to a
more clinically relevant (likely more expensive) models? What model
systems should be used before human translational studies?
2.1. Cell, tissue and organ culture models for ENS formation
2.1.1. Models of cells with ENS-forming competence
Enteric neural crest-derived cells are or include by deﬁnition
the “right kind” of cells to form ENS; they can be harvested from
the embryonic and postnatal gut. (Enteric neural crest-derived
cells include differentiated ENS cells such as neurons and glial
cells, as well as undifferentiated cells including ENSCs. Distin-
guishing between ENS glial cells, undifferentiated cells and enteric
neural stem cells (ENSCs) remains a challenge, especially for live
cell sorting; see Section 4). For mice, expression of reporters under
the control of ENS regulatory elements (Corpening et al., 2011;
Shibata et al., 2010) facilitates isolation of live enteric neural crest-
derived cells by ﬂuorescence-activated cell sorting (FACS) (Hotta
et al., 2013), but this is not applicable to similar cells from humans.
Neural crest-derived cells can be isolated from dissociated human
(and rodent) gastrointestinal tissue by FACS after immunolabelling
for the cell surface protein p75 (Chalazonitis et al., 1997; Walters
et al., 2010) or from avian gut using the HNK1 antibody (Rollo
et al., 2015). The isolated neural crest-derived cells, or at least a
sub-population thereof, can be propagated (although this seems
limited) in culture and studied in vitro or transplanted into re-
cipient bowel. These cells, particularly those of human origin, are
excellent models to test the capacities of ENS replacement. The
rodent cells are readily obtainable but the human patient-derived
cells require a close relationship with a clinical department as well
as having particular ethical requirements (Hagl et al., 2013b).
Mouse and human pluripotent progenitor cells (ES and iPS
cells) can be differentiated into “ENS-like” cells (Chambers et al.,
2013). These pluripotent progenitor cells have the capacity to
proliferate limitlessly, and iPS cells can be patient-derived and are
therefore autologous and immunologically ideal. Theoretically
these are the perfect clinical model cells but at present, the ENS
differentiation conditions are not optimized.
2.1.2. Models of the bowel with enteric neuropathy
For therapeutic use, some form of ENS-competent cells must be
combined with the patient’s affected bowel. What would be a
model for this bowel? Recipient ganglionated gut tissue can of
course be obtained from a variety of normal sources and can be
colonized by ENSCs in vivo in the mouse (Hotta et al., 2013), but
this is not a model for any clinical condition. Aganglionic gut can
be used in cell/tissue combination assays as a model for e.g. HSCR
colon. This can be isolated from wild type mouse, rat and avian
embryos prior to colonisation by ENSCs (Allan and Newgreen,
1980; Newgreen and Hartley, 1995; Young et al., 1998). This model
bowel is entirely devoid of NC-derived cells (i.e. aneural ), so as
well as being less mature as a tissue, it is not a perfect model for
the HSCR patient’s distal colon which is aneuronal: it lacks enteric
neurons but possesses extrinsic nerve ﬁbers and some NC-derived
glia. Aneuronal distal gut can be obtained from various mutant
rodents (e.g. Ret  / mice) even at post-natal stages (where sur-
vival permits), and this is a preferred model of the patient colon,
including overgrowth of extrinsic nerve ﬁbres, as in the human.
Aneuronal distal gut can also be obtained from avian embryos
after vagal NC ablation (Yntema and Hammond, 1954) or after
intestinal transection (Meijers et al., 1989) performed in ovo.
However there are differences in structure and maturity of the
avian colon and its extrinsic innervation (e.g. from Nerve of Remak
as well as via the pelvic plexus). These differences mean that it is
useful for basic questions but less useful as a clinical model.Please cite this article as: Burns, A.J., et al., White paper on guidelines
neuropathies. Dev. Biol. (2016), http://dx.doi.org/10.1016/j.ydbio.2016Aneuronal gut tissue may be obtained from post-natal human
distal colon tissue available from resections for HSCR (Rollo et al.,
2016). Obviously this is ideal in principle but problems, especially
of extended-term survival and growth ex vivo, have not been fully
worked out yet. These technical difﬁculties especially apply when
they involve large explants of colon tissues, as would be required
to model treatments of the colon of post-natal patients.
In regard to aneuronal colon models, a recent paper describes
late (i.e. post-natal) enteric neurogenesis from Schwann cell pre-
cursors in the mouse (Uesaka et al., 2015). The importance of this
population for supply of enteric neurons will need to be evaluated
in other animal, and human, models.
Gut tissue that models less extreme neuropathologies can be
obtained from relevant mouse mutants (see below). As well as
these complete gut tissues, decellularized gut can be obtained by
careful detergent extraction (Totonelli et al., 2012); this may be
useful for testing the role of gut ECM in ENS formation in the
absence of living mesodermal, endodermal and endothelial cells.
2.1.3. Cells with ENS-forming competence, and affected bowel:
models that bring the two together
Co-culture systems that are simplest to perform combine an-
euronal gut tissues in vitro with ENS-competent donor cells.
In vitro cultures on a solid substrate lead to dissolution of gut 3D
structure, so organotypic methods have been used for rodent and
avian gut. Gut segments grown on or in a matrix (e.g. collagen gel)
or in ﬂuid medium (Natarajan et al., 1999), or supported only at
each end (Hearn et al., 1999) have been used to preserve 3D tub-
ular gut form. These offer acceptable culture for periods of 4–8
days, allowing ENS cell proliferation, migration and differentiation
(Hearn et al., 1999; Wang et al., 2011). Gut can also be cultured for
weeks as transverse slices with preservation of 3D architecture
(Metzger et al., 2007). Differentiation and a degree of morpho-
genesis of the gut tissue occurs in vitro but the gut does not greatly
increase in size as it would in vivo. These techniques are ideal for
whole mount ﬂuorescent (antibodies, EdU, etc.) imaging and for
time-lapse recording using ﬂuorescent reporters (Druckenbrod
and Epstein, 2007; Nishiyama et al., 2012; Young et al., 2004), and
support limited functional studies. These in vitro assays are com-
patible with cell and tissue combinations from different species
(Almond et al., 2007) because of the absence of immune
responses.
For treatments of infants and children, the bowel will be growing,
and this can be modelled using systems that supply blood to the host
tissue. The simplest technique that provides blood to host tissues for
avians, is chorio-allantoic membrane (CAM) grafts (Allan and New-
green, 1980), where extensive gut elongation occurs. In ovo transplants
(Le Douarin and Teillet, 1973) and intracoelomic grafts (Nagy and
Goldstein, 2006) are also useful, but they are technically more difﬁ-
cult; in most cases CAM grafts would answer the same questions.
These avian-based grafts permit xenografting since they commence
before the onset of immune surveillance. Unfortunately, mammalian
gut growth in CAM grafts seems impaired, possibly because the larger
and less deformable avian red blood cells (Windberger and Baskurt,
2007) have difﬁculty negotiating mammalian capillaries. Moreover
the avian system models embryonic events whereas clinically ap-
propriate models would need to replicate post-natal stages. For rodent
tissues, renal capsule grafts (Cass et al., 1992; Young et al., 1998) are
useful even for extended periods (months) in contrast to the short
duration of the avian grafts (CAM o9 days, intracoelomic o3 weeks).
Post-natal human tissues can also be supported in renal capsule grafts
to mice with severe combined immunodeﬁciency (SCID). As well as
histology and immunolabelling, neurophysiological tests such as
contractility responses to electrical and chemical stimuli (Newgreen
et al., 1980) can be applied to these long-term grafts but their use-
fulness for studies of coordinated gut motility is impaired because theconcerning enteric nervous system stem cell therapy for enteric
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because the more mature tissue is more opaque.
These ex vivo models provide base-line information on the clonal
and population expansion abilities of ENSCs, their ability to populate
colonic tissues and assemble into ganglia in the correct position, to
differentiate into the many different ENS cell types and in the ap-
propriate ratios, and to connect via neurites and establish at least
some level of ENS function. Yet these are “hurdle requirements”; a
failure of ENS self-organisation in these models would suggest success
could not be attained in a clinical setting, but success with these
models (and much has been attained already) is a long way from
predicting clinical utility.
2.2. Whole animal models of ENS pathologies
Stem/progenitor cell therapy to treat human ENS pathology
will inevitably involve trials with whole animal models. The ideal
models should have phenotypes (and genotypes) that resemble
the human conditions described in Section 1. Developmental
stage-wise, they will need to resemble the post-natal human co-
lon, when enteric neuropathies are typically diagnosed.
2.2.1. Rodent models
Most studies to date use animal models of HSCR (Burzynski et al.,
2009; Zimmer and Puri, 2015). Loss-of-function mutations in RET are
the most common cause of HSCR in humans but the disease genetics
are complex, involving non-coding as well as coding sequences. Fur-
thermore there are many other gene defects that predispose to HSCR
(Amiel et al., 2008). Mouse models are available with spontaneous and
engineered mutations in essentially all of the HSCR-associated genes
(e.g. Ret, GDNF, GFRa1, ET3, EdnrB, Sox10; see JAX database for many
types, reviewed by (Zimmer and Puri, 2015) and there is also the
important rat EdnrB model (Ceccherini et al., 1995). These rodent
models are an excellent mimic of human HSCR because of the shared
gene defects, but there are some obvious differences. For example,
Retþ / mice (e.g. 129S/Sv-Rettm1Cos/J) are asymptomatic, whereas hu-
mans with familial RET mutations are affected but with incomplete
penetrance, estimated at about 70% for males and 50% for females
(Attie et al., 1995). However, titrating Ret expression in mice to about
30% results in human HSCR-like phenotype with incomplete but
male-weighted penetrance (Uesaka et al., 2008). Differences in gene
dosage should be borne in mind before predicting human responses
on the basis of rodent results.
The genetic background of inbred rodents also has important ef-
fects on ENS morphogenesis and disease phenotypes (Dang et al.,
2011; Walters et al., 2010). This observation suggests that in outbred
human populations there may also be diverse and unpredictable re-
sponses to cell transplantation because of unknown genetic modiﬁer
effects. Even now, a reﬂection of this variability is that a technically
ﬂawless HSCR resection/anastomosis is not a reliable predictor of long
term outcome. It will be necessary to demonstrate robustness of re-
sults in several mouse strains. However, the unpredictability based on
the genetic unknowns of individual humans will gradually recede as
Whole Genome Screening becomes economically feasible.
ENS repair for a severe enteric neuropathy like HSCR to a func-
tionally adequate stage would require time after delivery of ENCDCs,
and in post-natal humans this would be available by performing a
variant of the Swenson colonostomy procedure as a surgical holding
measure while the “new” ENS adapts in the retained indwelling distal
colon, prior to ﬁnal reparative anastomosis. Even if matched for donor
and host strains (Hotta et al., 2013), the size and delicacy of neonatal
mice render such surgical approaches extremely challenging (Zhao
et al., 2009), and functional assays to judge progress, such as mano-
metry, are not yet possible. In any case, post-natal survival due to the
gut disease and/or other defects is typically short. We therefore re-
commend against reparative cell emplacement and surgery trials inPlease cite this article as: Burns, A.J., et al., White paper on guidelines
neuropathies. Dev. Biol. (2016), http://dx.doi.org/10.1016/j.ydbio.2016neonatal mice, despite the appropriate mutants. Larger animal mod-
els, starting with rats (Stamp et al., 2015), will overcome this problem
because intestinal stoma creation is possible and is tolerated for ex-
tended periods.
An alternative strategy is to use mice with ENS defects that are not
fatal. For example, Gdnfþ / mice have hypoganglionosis throughout
the gastrointestinal tract (Flynn et al., 2007; Gianino et al., 2003) with
impaired colonic motility, poor muscle contractility, dilated colon and
fecal retention (Shen et al., 2002). These mice have a normal life ex-
pectancy (unlike many HSCR models), so long-term outcomes fol-
lowing experimental procedures can be studied in vivo. Also, since
endogenous ENS cells are present, interactions (inductions, connec-
tions) between transplanted cells and the host ENS may be studied.
Most importantly, this line would permit analysis of intestinal motility
many months after transplantation. The Gdnf-ﬂox line (B6.129S1(Cg)-
Gdnf tm1.1Neas/J) is also readily available, but the relevance of this model
to human disease is uncertain since technical challenges analyzing
neuron density in human specimens make ascertainment of hypo-
ganglionosis challenging.
Achalasia, an acquired loss of peristalsis in the esophagus and
impaired opening of the esophageal sphincter, may result from enteric
neuron degeneration, especially nitrergic neurons. The mouse genetic
model, Nos1tm1Plh/Nos1tm1Plh, has very low (not zero) levels of nNOS (in
brain) and a complex multi-organ phenotype, and is a more extensive
disease than human achalasia (Huang et al., 1993). Not only is there
impaired relaxation of the lower esophageal sphincter, but also of the
pyloric sphincter (Mashimo and Goyal, 1999), ileum (Mang et al.,
2002) and proximal colon (Anitha et al., 2008), and an absent recto-
anal inhibitory reﬂex (Terauchi et al., 2005), and these mice also have
gastroparesis, or impaired emptying of the stomach (Mashimo et al.,
2000). These digestive dysmotilities all occur in humans although
often separately. This model offers several sites along the gastro-
intestinal tract for transplantation. Embryonic mouse neural stem cells
injected into the pylorus of Nos/ mice has been reported to dif-
ferentiate rapidly into Nos-expressing neurons and symptoms (Micci
et al., 2005) of gastroparesis are also alleviated. This extraordinary
result requires much further work to conﬁrm it, and to ascertain the
mode of functional effects.
The Spry2tm1Ayos/Spry2tm1Ayos mouse also shows functional oeso-
phageal achalasia with dilated oesophagus, but with hyperganglio-
nosis of the ENS (unlike human achalasia) (Taketomi et al., 2005). This
is superﬁcially similar to human MEN2B, but it is genetically different.
Its usefulness as model for human disease treatment does not seem
high at present.
Diabetes is associated with reduced expression of NOS1 neu-
rons as seen in diabetic gastroparesis (Grover et al., 2011), parti-
cularly in female patients. In diabetic mice, comparable changes
occur in the ENS, including loss of nitrergic neurons (Bagyanszki
and Bodi, 2012). Mice fed a high-fat diet also develop type 2 dia-
betes as well as obesity, and intestinal dysfunction with lowered
numbers of nNOS and VIP neurons in the duodenum (Stenkamp-
Strahm et al., 2013). In view of the clinical importance of diabetes
and obesity in human health, these mice are particularly im-
portant targets for clinically motivated studies aiming at stemming
the loss of these cells, or replacing them.
Although numerous mouse mutants have been very informative
about the role played by certain genes in ENS development, one also
needs to bear in mind possible non-cell-autonomous roles of these
genes, and how complexities in gene function could affect future cell
therapies for enteric neuropathies. For example, arguably the best
known ENS development gene, Ret, has been shown to be involved in
ENS precursor cell survival, migration, proliferation and differentiation
(reviewed in (Sasselli et al., 2012b)). However, in studies where wild-
type ENS progenitors were transplanted into the vagal NCC pathway
of Ret-deﬁcient embryos, these wild-type cells were only able to co-
lonize the proximal foregut, demonstrating a non-cell-autonomousconcerning enteric nervous system stem cell therapy for enteric
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2008). Clearly this could be important should ENS stem cells, or cells
from other sources, be transplanted into HSCR patients that have a RET
mutation. More studies need to be performed to determine the effects
of mouse mutations not only on enteric NCCs speciﬁcally, but also on
their local environment.
2.2.2. Avian and Fish models
Formation of the ENS in Aves is comparable to that in mam-
mals, with differences in detail: the colonic SMP is colonised ﬁrst
(Burns and Douarin, 1998) unlike the MP-ﬁrst sequence in mam-
mals (McKeown et al., 2001), neuronal differentiation lags further
behind the colonising wavefront than in mice (Conner et al., 2003;
Nagy et al., 2012) and trans-mesenteric migration (Nishiyama
et al., 2012) from midgut to colon does not occur. Despite the
dearth of genetic ENS models in Aves, whole animal models of
HSCR can be produced by microsurgical vagal NC ablation (Yntema
and Hammond, 1954) or intestinal transection (Meijers et al., 1989)
at early stages in ovo as well as by pharmacological endothelin
signalling inhibitors (Gasc et al., 2015). The HSCR-like phenotype
of NC ablation can be saved by NC replacement (Barlow et al.,
2008), but this is early embryonic, and is therefore of little use as a
model of any anticipated clinical approaches to human post-na-
tally detected enteric neuropathies.
The Zebraﬁsh is an amenable model system (Shepherd and Eisen,
2011) with ENS colonization similar to that of amniotes with some
differences. ENCDCs do not migrate within the gut mesenchyme but
as two parallel chains just outside the gut. Also the later ganglionation
as in the mammalian and avian ENS does not occur. Colorless, a Sox10
mutant, is a HSCR model (Dutton et al., 2001; Kelsh and Eisen, 2000),
while lessen has ENS cells along the entire gut but at lower cell den-
sity, like hypoganglionosis (Pietsch et al., 2006). However their use-
fulness in the context of developing reparative procedures for human
infants and children is limited.
Despite practical uselessness for modelling repair procedures,
these models, avian and ﬁsh, have provided, and will continue to
provide, vital information on ENS formation. In particular they may be
among the quickest and most economical avenues for obtaining in-
formation on growth factor requirements for the induction of cells
with ENS-forming capacities (Reichenbach et al., 2008; Simkin et al.,
2013), and this would most likely be translatable to human iPS cells.
Further, both avian and zebraﬁsh are excellent model systems for high
throughput reverse genetic screening (e.g. using morpholinos and
CRISPR knockdown technologies) of candidate genes implicated in
ENS formation and for chemical screening of compounds that may
affect enteric NCC migration, proliferation and/or differentiation
in vivo. Although CRISPR technology is still in its infancy, particularly
in the chick, chemical screening has recently been performed using
zebraﬁsh and chick to test the idea that certain medicines, taken
during early human pregnancy, might alter HSCR risk (Schill et al.,
2016).
2.2.3. Porcine models
Despite the genetic and descriptive similarities, the above models
differ vastly from human neonates in the size of the ﬁeld of re-
colonization required, so large animal models, despite the expense,
will be necessary for ENS stem cell therapy proof-of-principle. For this
pigs offer the advantages of similarity to humans in size, anatomy,
physiology, and genetic makeup (Sri Paran et al., 2009). The pig is
already a model for human physiology and a surgical model, with
considerable ENS data (Barbiers et al., 1994; Brown and Timmermans,
2004; Montedonico et al., 2006). Pigs tolerate intestinal surgery and
stoma creation with fortitude (J.B. Furness, personal comm.). We are
not aware of porcine ENS pathology models, but the BAC process (see
Section 1, p5 and below) could be employed to induce localised
aganglionosis or hypoganglionosis to produce models of humanPlease cite this article as: Burns, A.J., et al., White paper on guidelines
neuropathies. Dev. Biol. (2016), http://dx.doi.org/10.1016/j.ydbio.2016enteric neuropathies. Potentially transplantable porcine ENS cells can
be isolated by p75-FACS (B. N. Rollo, personal comm.). Autologous
implanted cells would be required for cell survival past 1–2 weeks
post-implantation, unless using immunodeﬁcient pigs. However im-
munosuppression is achievable in pigs with a cocktail of drugs
(Gruessner et al., 1996). Additionally, there are pig models with severe
combined immunodeﬁciency (SCID) including SCID Yorkshire pigs
(Basel et al., 2012), and the SCID Göttingen minipig (Lee et al., 2014).
SCID pigs are available in U.S.A. from the National Swine Resource and
Research Center (http://nsrrc.missouri.edu). The Goettingen minipig
model has real advantages for adult studies because commercial adult
pigs are large and cost more to feed and house, and are more difﬁcult
to handle. However, for paediatric surgery trials which would require
only a limited survival time, the minipig does not offer signiﬁcant
advantages to offset their generally greater cost per weanling unit,
availability and supply.
2.2.4. Chemically-induced models
Chemically induced aganglionosis, by topical application in vivo of
BAC to small or large bowel, can result in local aganglionosis/hypo-
ganglionosis (Pan et al., 2011; Wagner et al., 2014). This is not ENS-
speciﬁc at the outset, but mesodermal cells are less affected/recover
better from BAC, than the ENS. Aganglionosis/hypoganglionosis in the
BAC model might not be permanent and neurons re-populate the
lesioned area in time (Hanani et al., 2003).
2.3. Conclusions
Much information on ENS formation and on potential therapies for
ENS diseases will continue to be gathered from in vitro models of
varying types, in particular on comparison of the complexity of the
distribution and wiring pattern and of the spectrum of neuronal dif-
ferentiation in “replacement ENS” versus normal ENS. In addition
detailed functional data will soon emerge from mouse whole animal
models on, for example, control of smooth muscle function by re-
placement ENS. These extensions of current research using rodent,
avian and ﬁsh can be anticipated in the near future.
There seem to be two next steps of equal importance. The ﬁrst
is a shift to the rat: much of the experience gained with the mouse
will be applicable to this genetically convenient model, with the
additional advantage that anticipated surgical approaches – co-
lostomy, transfer of cells to the distal colon, and later bowel ana-
stomosis – required for human HSCR postnatally are possible in
the EdnrB rat HSCR model (Stamp et al., 2015). The second is to
approach the potential scaling difﬁculty. The favourable results in
the mouse suggest that transplantation therapies for ENS diseases
will be possible in humans in principle, but all events of ENSC
replacement for an ENS disease i.e. cell proliferation, migration,
aggregation, differentiation, and wiring, must be done on a vastly
larger scale in human patients than in mouse or even rat. The
sheer size difference may lead to failure in clinical practice. It is
imperative that a step to a human-scale model, the pig, be made,
and this should be commenced sooner rather than later.3. What is the optimal source of stem cells for enteric neuro-
nal replacement?
During embryogenesis, neural crest progenitors colonise the de-
veloping bowel and ultimately give rise to all the neurons and glia of
the ENS. However, the optimal source of stem/progenitors cells to
generate a “new” ENS in the defective portion of bowel of patients
with enteric neuropathies has yet to be established. Here we identify
the main candidate stem/progenitor cell populations and highlight the
respective pros and cons of each cell type in the context of enteric
neuronal replacement. Of note is an exciting study recently publishedconcerning enteric nervous system stem cell therapy for enteric
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rected human embryonic stem (ES) cells towards a vagal neural
crest (i.e. ENS precursor) lineage and showed that these ES-derived
cells, when transplanted into the vagal neural crest region of de-
veloping chick embryos and into the cecum of young mice, mi-
grated to the chick bowel and colonized the entire mouse colon
respectively. In vitro, they enhanced smooth muscle differentiation,
and differentiated into enteric neuronal and glial cells. Perhaps
most interestingly from a cell therapy point of view, when the cells
were transplanted into the cecum of Ednrb / mice, which have
megacolon and usually die in early post-natal stages, all mice sur-
vived, and had transplanted cells along the colon, implying rescue
of the aganglionic gut phenotype. These studies, for the ﬁrst time,
outline an efﬁcient strategy to derive and purify enteric precursors
from human ES cells that could potentially enable the large-scale
production of speciﬁc human enteric neurons for cell therapy on
demand (Fattahi et al., 2016). Nevertheless, before this becomes a
reality some issues remain to be addressed such as the effect of
transplanted cells on bowel motility, and long-term safety (Heuck-
eroth, 2016).
3.1. Enteric nervous system neural stem/progenitor cells
It has been established in rodents and in humans that resident ENS
neural stem/progenitor cells exist in the GI tract in the postnatal
period (Bixby et al., 2002; Bondurand et al., 2003; Kruger et al., 2002).
HSCR is the result of an absence of the ENS in the distal bowel,
however the remaining ganglionated bowel contains a mostly nor-
mally functioning ENS and likely the same resident neural stem/pro-
genitor cells found in normal bowel. This offers the enticing possibility
of using patient-derived, autologous neural stem/progenitors cells
isolated from the normo-ganglionated regions of HSCR patient bowel
as the source of cells to ultimately transplant and treat the disease
(Rollo et al., 2016). There are several likely major beneﬁts of using ENS
neural stem cells to treat enteric neuropathies. These include:
(i) ENS neural stem cells have received the appropriate prior
“education” to become enteric neural stem/progenitor cells.
ENS-derived neural stem cells have arisen from the original
source, chieﬂy the vagal neural crest. They have received the
appropriate signals throughout development to become en-
teric neural crest cells, expressed the appropriate genes and
have likely already given rise to functional mature neuronal
daughter cells. A ﬁrst step of this may be the acquisition of a
vagal HOX code (Kam and Lui, 2015). A previous study showed
that even vagal neural crest cells are not efﬁcient at generating
enteric neurons if they do not pass through their normal
migratory route and receive speciﬁc cues, including retinoic
acid signalling (Simkin et al., 2013).
(ii) Patient-derived autologous cells would avoid the need for
immune suppression after transplantation. Stem cells from the
normal regions of patient’s bowel can be expanded in vitro
and transplanted back into defective regions of bowel of the
same patient.
iii) Gut derived ENS stem cells have proven ability to generate
enteric neurons. Resident enteric neural stem cells have likely
already given rise to functional neuronal daughter cells during
generation of the ENS. Further, recent studies in mice have
demonstrated that ENS-derived neural progenitors can give
rise to neurons of the appropriate neurochemical and elec-
trophysiological phenotype following transplantation into the
postnatal colon (Hotta et al., 2013).
Caveats to the use of ENS-derived progenitor cells for cell
therapy include:Please cite this article as: Burns, A.J., et al., White paper on guidelines
neuropathies. Dev. Biol. (2016), http://dx.doi.org/10.1016/j.ydbio.2016(i) Gut derived ENS progenitors have limited capacity for self-re-
newal (Bondurand et al., 2003; Kruger et al., 2002) and large
numbers of cells will be required to colonise even modest regions
of aganglionic bowel. Therefore if in vitro expansion of these cells
is limited, this could prove to be a major hurdle.
(ii) Gut derived ENS progenitors are difﬁcult to purify. We currently
lack robust cell surface markers for prospective isolation of enteric
neural crest stem cells from the post-natal bowel. Recent studies
in rodents have employed ﬂuorescent transgenes from promoters
of genes that encode proteins that are not expressed on the cell
surface, so using these genetic markers for cell sorting in humans
is not simple (Corpening et al., 2011).
iii) Patient-derived ENS progenitor cells will possess genetic mu-
tations that caused the disease we need to treat. This may not
be a problem for most children with Hirschsprung disease
where the proximal bowel ENS usually works well, but might
be problematic for some types of neuropathic chronic in-
testinal pseudoobstruction syndrome (CIPO) (e.g., POLG mu-
tation, TYMP mutation). For these problems, in vitro manip-
ulation or correction of the genetic defects using CRISPR/Cas9
or TALEN technology might be required, but this raises safety
questions inherent to gene therapy (i.e., neoantigens and
malignant transformation).
3.2. Non-ENS neural stem/progenitor cells
There are numerous other potential non-ENS sources of neural
stem cells which could conceivably be used for cell therapy for
enteric neuropathies. Here we discuss the pros and cons of each
potential non-ENS source of cells for treatment of enteric
neuropathies.
3.3. Central nervous system (CNS) neural stem cells
CNS neural stem cells can effectively treat numerous CNS neuro-
pathies (Barker et al., 2013). Further, studies have shown that CNS-
derived neural stem cells can survive and make contributions to
functional improvements in gut motility disorders (Kulkarni et al.,
2011; Micci et al., 2005, 2001). The beneﬁts of CNS neural stem cells
include:
(i) Close developmental association of the CNS/ENS. The vagal neural
crest which forms the majority of the ENS arises from the neural
tube adjacent to the developing caudal hindbrain and there are
close similarities in the range of neurotransmitters expressed by
CNS and ENS cells.
(ii) CNS neural stem cells are a well characterised population, whose
culture conditions are well established and which possess an
extensive capacity for self-renewal (particularly fetal derived
neural stem cells).
Caveats for the use of CNS neural stem cells include:
(i) CNS-derived stem cells are not easily accessible since isolation
involves highly invasive procedures, particularly accessing stem
cell rich regions of the brain. Therefore, use of CNS neural stem
cells for treatment of enteric neuropathies is unlikely.
(ii) CNS-derived stem cells may not be as efﬁcient at migration
and neuronal differentiation in the gut as ENS neural pro-
genitors (Findlay et al., 2014).
3.4. Pluripotent stem cells
Both human embryonic stem (ES) cells and induced pluripotent
stem (iPS) cells have the capacity to give rise to any cell of the
body, including those of the ENS. Therefore, there is great interestconcerning enteric nervous system stem cell therapy for enteric
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treat enteric neuropathies (Heuckeroth, 2016). Potential beneﬁts
include:
(i) ES and iPS cells have a near unlimited capacity for self-re-
newal. This means that large numbers of cells likely to be re-
quired for ENS cell therapy can be produced from these plur-
ipotent populations.
(ii) ES and iPS cells can be manipulated in vitro to induce neural
crest-like phenotype (Chambers et al., 2009; Denham et al., 2015;
Hotta et al., 2009; Lee et al., 2010, 2007) and the subsequent
engraftment or coculture with embryonic gut tissue (chick or
mouse) can induce enteric neuron-like cells (Denham et al., 2015;
Hotta et al., 2009; Sasselli et al., 2012a). Recently, as mentioned
above, protocols to obtain large numbers of ENS neural progeni-
tors, that colonised the gut of Ednrb mutant mice following
transplantation, have been published (Fattahi et al., 2016).
iii) iPS cells (in contrast to ES cells) can be used for autologous
transplantation; a patient’s own skin or blood sample could be
used to generate the iPS cell line that is used for transplantation.
(iv) ES cells and iPS are easily genetically manipulated. This may be
important because some enteric neuropathies (e.g. HSCR, some
types of CIPO) result from identiﬁable genetic changes that may
need to be addressed before transplantation. iPS cells are easily
genetically manipulated using CRISPR/Cas9, TALENs or other tra-
ditional gene manipulation techniques. However off-target effects
must be considered when assessing safety for cell transplantation.
Caveats for using ES and iPS derived cells to treat enteric
neuropathies.
(i) Ethical issues arise because ES cells are derived from human
embryos. This problem does not occur with iPS cells that can
be produced from readily available post-natal cells with little
risk.
(ii) Transplantating ES- or iPS-derived cells raises safety concerns,
especially the possibility of tranplantating residual pluripotent
stem cells which may be tumorigenic under certain conditions.
iii) Recapitulating embryogenesis in a dish, to generate enteric
neurons from pluripotent stem cells, is difﬁcult, costly and
often inefﬁcient using current techniques.
3.5. Other neural crest-derived stem cells sources
Numerous other sources of neural crest-derived stem cells reside
in somatic tissues and could potentially be used for enteric neuronal
replacement. These include sciatic nerve (Bixby et al., 2002), hair
follicle bulge (Sieber-Blum et al., 2004), and dental pulp (Gronthos
et al., 2000; Stevens et al., 2008). Although these populations are
neural crest derived, they arise from varying axial levels of the neural
tube, may have inappropriate epigenetic memory, and it is not known
if these cells are capable of generating enteric neurons and glia.
It is currently difﬁcult to deﬁne the optimal source of cells for
enteric neuronal replacement. Each potential population of cells has
their own beneﬁts and caveats that need to be exploited and over-
come, respectively, to prove efﬁcacious for enteric neuronal replace-
ment. Until such time, studies should not be limited to any one po-
pulation of cells, as information gleaned from each study will beneﬁt
the ﬁeld as a whole.4. Identifying, selecting, harvesting and optimizing isolation
of gut-derived ENS progenitors/stem cells
Enteric neural progenitors, which appear to reside within the
ganglionated myenteric and submucous plexus of the gastrointestinalPlease cite this article as: Burns, A.J., et al., White paper on guidelines
neuropathies. Dev. Biol. (2016), http://dx.doi.org/10.1016/j.ydbio.2016tract, can be isolated from the gut by dissection, using specialized
culture conditions or by cell sorting. Techniques to isolate and culture
the myenteric (Jessen et al., 1978, 1983; Korman et al., 1988; Nishi and
Willard, 1985) or submucosal plexus (Surprenant, 1984) were devel-
oped in the late 1970s, and were even used for transplantation into
the CNS (Tew et al., 1994). Unfortunately, most techniques isolated
many non-ENS cells along with the ENS and the stem cells were only a
small subset of the ENS cells isolated. Only Jessen’s approach of
manually dissecting the colonic myenteric plexus from guinea-pigs
prior to dissociation delivered isolated pure ENS cells in small quan-
tities. All these strategies have now been adapted for the isolation of
enteric neural progenitors, and have been used, with variations, by
different groups.
The most common approaches for isolating fetal and post-
natal enteric neurons and glia, and their progenitors, begin with
enzymatic dissociation of the bowel using dispase and col-
lagenase followed by cell culture (Bondurand et al., 2003;
Metzger et al., 2009a, 2009b; Schafer et al., 2003). Although the
isolated cells are enriched for the ENS, cultures typically include
ﬁbroblasts, smooth muscle and immune cells in undeﬁned
combinations that could inﬂuence culture results or transplan-
tation success. Indeed culture conditions may also dramatically
alter cell composition with some cell types proliferating more
than others. For example, some methods use FGF, EGF and
chicken embryo extract, whereas others use only deﬁned growth
factor combinations. A detailed analysis of the amount of neural
stem cells and their differentiation potential is necessary to allow
comparisons between the different protocols. This is one of the
basic tasks that have to be performed to allow a standardization
of the "production" of neural crest derived stem cell for cell
therapies. Depending on the reason for transplantation, the dif-
ferentiation of speciﬁc subpopulations might be beneﬁcial. So the
inﬂuence of individual growth or neurotrophic factors upon the
differentiation outcome is crucial, but the appropriate knowledge
is yet to be provided.
One way to improve the purity of ENS progenitor cultures is by
cell sorting. For this purpose, FACS appears to provide better de-
ﬁned cell populations than bead-based immunoselection. How-
ever, cell sorting necessitates very speciﬁc cell surface markers to
identify progenitors within the enteric cell population or the use
of transgenic mouse models where neural crest cells or progeni-
tors are genetically labelled (e.g. Nestin, Wnt, Sox2). Numerous
sorting attempts have been performed using antibodies against
HNK-1 (aka NC-1) (Pomeranz et al., 1993), p75 (Chalazonitis et al.,
1998; Wilkinson et al., 2015), integrin α4 (Bixby et al., 2002) or
CD49 (Joseph et al., 2011), but when used individually they may
fail to isolate the entire neural progenitor population. Whether
this is of importance for transplantation success has yet to be
determined as it is not yet known whether pure, well deﬁned cell
populations are better at rescuing the ENS than mixed cell
populations.
One major problem for advancing stem cell therapy is isolating
and obtaining sufﬁcient numbers of ENS cells, particularly from
post-natal bowel. Early protocols for the isolation of human
myenteric plexus for example, yielded only single ganglia from
postnatal gut (Schafer and Mestres, 1997), but more recent pro-
tocols using puriﬁed collagenase allow the isolation of pure
myenteric plexus from human gut in larger quantities (Grund-
mann et al., 2015). Isolation of human submucosal plexus is also
possible, but does not deliver coherent networks, as seen for the
myenteric plexus. Moreover, there are plenty of neural stem cells
in between the smooth muscle cells. These cells can only be iso-
lated with speciﬁc markers for cell sorting. Whether the individual
stem cell populations in myenteric, submucous and muscle layers
are equal has to be analysed in more detail.concerning enteric nervous system stem cell therapy for enteric
.04.001i
A.J. Burns et al. / Developmental Biology ∎ (∎∎∎∎) ∎∎∎–∎∎∎104.1. Optimizing, propagating, and priming stem cells prior to
transplantation
To date, it remains unclear how many cells are necessary to colo-
nize a deﬁned area of aganglionic gut. Depending on the methods of
cultivation and transplantation, as well as possible genetic or chemical
modiﬁcations, the necessary number may vary signiﬁcantly. In hu-
mans, the amount of available tissue for the isolation of enteric neural
progenitors is restricted and only small numbers of neural stem cells
might be available. It is therefore crucial to develop techniques to
increase the number of ENS progenitors in culture prior to trans-
plantation. Progenitor numbers can be expanded in culture by using
mitogens such as GDNF, FGF and EGF. In addition, factors that have
been effective for CNS-derived neural stem cells might also be ap-
plicable for the ENS (e.g. LIF, Interleukins, etc.). Recently it was de-
monstrated that granulocyte-colony-stimulating factor (GCSF) can
signiﬁcantly increase the amount and size of enteric neurospheres
(Schuster et al., 2014b). Bacterial lipopolysaccharides, which seem to
maintain the stemness of the enteric neural progenitors (Schuster
et al., 2014a) may also be used to enhance the proliferation of enteric
neural progenitors. Other important factors include Endothelin-3
which seems to maintain the multilineage potential of ENS precursors.
This is a very important aspect, due to the fact that neural progenitors
appear to lose their stem cell characteristics in long term cultures
(Lindley et al., 2009).
Neural progenitors are often cultured as neurospheres, but could
likewise be kept in adhesion cultures, or in a combined sphere-
adhesion culture, grown on polystyrol beads. Moreover, the speciﬁc
culture conditions, such as mimicking realistic oxygen concentra-
tions (Hegewald et al., 2011; Mohyeldin et al., 2010), might also be
an option to increase the yield of enteric progenitor cells since
Hegewald et al. showed that the amount of p75-positive cells in
culture increased when oxygen tension was reduced. Reduced
oxygen tension might even be used to enhance the speciﬁc differ-
entiation of neuronal subtypes. In CNS-derived stem cells, a re-
duction of the ambient oxygen tension to 3% led to a signiﬁcant
increase in the yield of dopaminergic neurons (Krabbe et al., 2009).
To increase the developmental potential of the cells for trans-
plant, a pretreatment with neurotrophic factors or genetic mod-
iﬁcation strategies could be applied, as has already been demon-
strated for cell therapies in the CNS (Fjord-Larsen et al., 2005).
While genetic modiﬁcation might be harder to control, a chemical
priming with neurotrophic factors prior to transplant, as well as
the use of speciﬁc devices (e.g. lipid nanocarriers) for controlled
drug release might be advantageous.
4.2. Conclusions
We are still at the stage where the advantages and disadvantages
of various approaches for the isolation, expansion and optimisation of
neural progenitors/stem cells from the human ENS need to be in-
vestigated more intensely. At the current time there is no optimal and
standardized way of isolating and expanding ENS progenitors while
maintaining their stem cell properties. To address this, the ﬁeld will
need to develop culture conditions that mimic, more realistically, the
neural stem cell niche of the ENS. Possible underexplored approaches
include using hydrogels for cell cultivation that can be modiﬁed and
tailor made to provide in vivo-equivalent conditions. Including me-
senchymal stem cells, myoﬁbroblasts, or even the gut microbiota
might help to maintain such a niche allowing in vitro expansion, but
growing cells under these conditions would necessitate development
of additional ENS precursor isolation procedures prior to transplan-
tation. There is also a need to develop cryopreservation strategies to
permit storage of enteric neural progenitors, while retaining their
characteristic features necessary for engraftment and colonization
after transplantation into gut.Please cite this article as: Burns, A.J., et al., White paper on guidelines
neuropathies. Dev. Biol. (2016), http://dx.doi.org/10.1016/j.ydbio.20165. How are “neurospheres”, and the neural progenitors within
them, best characterized?
Historically, the ﬁrst characterization of neural stem cells de-
rived from the central nervous system (CNS) dates back to the
discovery of adult neurogenesis by Altman (1969). However, it was
not until 1992 that cells with stem-cell potential were cultured in
vitro to form the free ﬂoating three-dimensional spheroids that
became known as neurospheres (Reynolds et al., 1992). Twenty
years later several groups adapted protocols for the isolation and
characterization of neurospheres from both rodent and human
gut, which appeared to be very similar to their CNS-derived
counterparts (Bondurand et al., 2003; Kruger et al., 2002; Rauch
et al., 2006; Schafer et al., 2003).
5.1. Characterisation of neurosphere-like bodies (NLBs) from animal
models
To assess the different cell types in a neurosphere, otherwise
known as a neurosphere-like body (NLB), it is critical to analyze dif-
ferent molecular markers, gene expression and/or biological functions
that distinctly characterize each cell population (progenitor, neuron,
glia cell, myoﬁbroblast, others; see Table 1 and Schweitzer et al. (2005)
and Anderson (1983)). Depending on the individual culture protocols
and markers used, NLBs from early postnatal mouse/rat gut are im-
munoreactive for typical neural differentiation markers after an in
vitro culture period up to 2 weeks (Belkind-Gerson et al., 2013; Binder
et al., 2015; Bondurand et al., 2003; Dettmann et al., 2014; Kruger
et al., 2002; Silva et al., 2008). A small fraction of NLB cells (o15%)
remain negative for all differentiation markers used, raising the pos-
sibility that at least a subfraction of the isolated cells that generate
neurospheres are undifferentiated progenitors or NSCs (Bondurand
et al., 2003). This assumption is supported by studies demonstrating
15–30% proliferative cells within postnatal murine neurospheres
after short-term BrdU or EdU pulse labeling (Mohr et al., 2013;
Theocharatos et al., 2013) will co-labeled with neural markers (TuJ1,
NOS, GFAP, Sox10, S100b) after a 96 h chase. After an extended culture
period under differentiation conditions around 65% of neurons were
co-immunostained with BrdU underlining that differentiated neurons
are indeed derived from undifferentiated progenitors (Almond et al.,
2007; Dettmann et al., 2014).
However, to date no deﬁnitive molecular marker of NSCs in
both the CNS and ENS has been found. None of the markers
currently used detects all progenitor subtypes at any given point
of time or region in development. Although some surface and
intracellular markers are highly expressed in enteric progenitors
during embryonic gut development of rodents (i.e. especially
Sox10, Sox2, RET, p75, Phox2b, EDNRB, Mash1, Nestin; reviewed
in (Obermayr et al., 2013; Sasselli et al., 2012b) most of these
markers are also expressed in differentiated neural cells (i.e. the
majority of postnatal ENS cells) or other cell types and therefore
discrimination of progenitors is not possible. Under standard
culture conditions about 20% of initial cell colonies are im-
munoreactive for the neurotrophin receptor p75 after 7 days in
vitro. If hypoxic culture conditions are used this potential stem
and progenitor cell fraction can be doubled within the same time
(Hegewald et al., 2011). However, it is very likely that truly un-
differentiated cells (i.e., NSCs that can fulﬁll the operational stem
cell deﬁnition in vitro and, most importantly, in vivo) represent
only a small percentage of the cells within the neurospheres
(presumably less than 2% based on earlier CNS studies (Gritti
et al., 1996). Interestingly, one study of postnatal rat neuro-
spheres identiﬁed typical markers of pluripotent cells such as
Sox2, Nanog and Oct4 in a relatively large subfraction of cells
even though most cells in NLBs are unlikely to have signiﬁcant
stem cell like properties (Hagl et al., 2013b). It will be interestingconcerning enteric nervous system stem cell therapy for enteric
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Table 1
Molecular markers expressed in proliferating and differentiated enteric neural cells/progenitors/neurospheres in vitro.
Stem/pro-
genitor
marker
Recognition Further cell
detection
Species
(M, H, R,
C)
References
Ret Receptor tyrosine kinase Neurons M, H Bondurand et al., 2003; Metzger et al., 2009a; Sribudiani et al., 2011
p75 Low-afﬁnity neurotrophin
receptor
Glia Neurons M, H, R Binder et al., 2015; Bixby et al., 2002; Hegewald et al., 2011; Hetz et al., 2014; Kruger
et al., 2002; Lindley et al., 2009; Lo and Anderson, 1995; Metzger et al., 2009a, 2009b;
Mohr et al., 2013; Sribudiani et al., 2011; Theocharatos et al., 2013
Nestin Intermediate ﬁlament type VI Neurons M, H, R Binder et al., 2015; Grundmann et al., 2015; Hagl et al., 2013b; Hetz et al., 2014;
Metzger et al., 2009a, 2009b, 2007Glia
Other
HNK-1-NCAM
(CD 57)
Integral membrane form of
N-CAM (neural cell adhesion
molecule)
Neuroepithelial
cells
M,R, C Schafer et al., 2003
Sox2 SRY (sex determining region-Y)
HMG box 2
Glia M, H Heanue and Pachnis, 2011; Hetz et al., 2014
Sox10 SRY (sex determining region-Y)
HMG box 10
Glia M, H Binder et al., 2015; Bondurand et al., 2003; Metzger et al., 2009b
Ki-67 Nuclear protein associated with
ribosomal RNA transcription
Neural M, H Binder et al., 2015; Hegewald et al., 2011; Metzger et al., 2009b
progenitors
Glia
BrdU, EdU Thymidine analogs Neural M, H Dettmann et al., 2014; Hegewald et al., 2011; Hetz et al., 2014; Metzger et al., 2009a,
2009b, 2007; Mohr et al., 2013; Theocharatos et al., 2013progenitors
Glia
pH3 Phospho-Histone 3 Neural M Binder et al., 2015
progenitors
Glia
Neuronal marker Recognition Further
cell
detection
Species
(M, H, R,
C)
References
TuJ1 Neuron-speciﬁc beta tubulin III M, H, R Binder et al., 2015; Bondurand et al., 2003; Hagl et al., 2013b; Hegewald et al., 2011;
Hetz et al., 2014; Metzger et al., 2009a, 2009b, 2007; Mohr et al., 2013; Suarez-
Rodriguez and Belkind-Gerson, 2004; Theocharatos et al., 2013
PGP9.5 Neuron-speciﬁc 27-kDa intracellular
C-terminal ubiquitinilated hydrolase
M, H Bondurand et al., 2003; Dettmann et al., 2014; Hegewald et al., 2011; Lindley et al.,
2009; Metzger et al., 2009a, 2009b; Rauch et al., 2006
HuC/D RNA-binding protein M, H Dettmann et al., 2014; Hetz et al., 2014; Mohr et al., 2013
Peripherin Type III Intermediate ﬁlament R Bixby et al., 2002; Kruger et al., 2002
Mash1 Mammalian achaete–scute homo-
logue 1
M Bondurand et al., 2003
MAP2 Microtubule-associated protein 2 H Metzger et al., 2009a
Neuroﬁlament
medium protein
(NFm).
Intermediate ﬁlament protein H Metzger et al., 2009a
160/200-kDa NF 160- and 200-kDa proteins of human
neuroﬁlament
M Suarez-Rodriguez and Belkind-Gerson, 2004
Tau Microtubule-associated protein M Suarez-Rodriguez and Belkind-Gerson, 2004
VIP Vasoactive intestinal peptide M, H, R Binder et al., 2015; Bondurand et al., 2003; Kruger et al., 2002; Metzger et al., 2009a,
2009b; Suarez-Rodriguez and Belkind-Gerson, 2004
nNOS Neuronal nitric oxide synthase M, H, R Binder et al., 2015; Bixby et al., 2002; Dettmann et al., 2014; Hegewald et al., 2011;
Kruger et al., 2002; Metzger et al., 2009a; Suarez-Rodriguez and Belkind-Gerson,
2004; Theocharatos et al., 2013
ChAT Choline acetyl transferase M, H Hegewald et al., 2011; Metzger et al., 2009a, 2009b
AChE Acetycholine esterase M Suarez-Rodriguez and Belkind-Gerson, 2004
CGRP Calcitonin gene-related peptide M, H Binder et al., 2015; Metzger et al., 2009a, 2009b; Suarez-Rodriguez and Belkind-
Gerson, 2004
NPY Neuropeptide Y M, H, R Binder et al., 2015; Bixby et al., 2002; Bondurand et al., 2003; Kruger et al., 2002;
Metzger et al., 2009a; Suarez-Rodriguez and Belkind-Gerson, 2004
Peptide YY Agonist of the neuropeptide Y
receptor
M Suarez-Rodriguez and Belkind-Gerson, 2004
Peptide P Neuromodulator and
neurotransmitter
M Suarez-Rodriguez and Belkind-Gerson, 2004
Galanin Inhibits secretion of transmitters or
hormones
M Suarez-Rodriguez and Belkind-Gerson, 2004
TH Tyrosine hydroxylase M, H, R Bondurand et al., 2003; Hagl et al., 2013b; Metzger et al., 2009a
Serotonin Neurotransmitter M, H, R Kruger et al., 2002; Metzger et al., 2009a
DβH Dopamine-beta-hydroxylase R Kruger et al., 2002
Glutamate trans-
porter EACC1
EAAC1 glutamate transporter, so-
dium-dependent
M Suarez-Rodriguez and Belkind-Gerson, 2004
Synaptophysin 38-kDa glycoprotein of presynaptic
vesicles
M Suarez-Rodriguez and Belkind-Gerson, 2004
Glial
marker
Recognition Further cell
detection
Species (M,
H, R, C)
References
GFAP Intermediate M, H, R Binder et al., 2015; Bixby et al., 2002; Bondurand et al., 2003; Dettmann et al., 2014; Hagl et al., 2013b;
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ﬁlament protein Hegewald et al., 2011; Kruger et al., 2002; Metzger et al., 2009a, 2009b, 2007; Mohr et al., 2013; Theo-
charatos et al., 2013
S100b Calcium-binding
protein B
M, H Binder et al., 2015; Dettmann et al., 2014; Hetz et al., 2014; Lindley et al., 2009; Metzger et al., 2009a,
2009b; Theocharatos et al., 2013
Others Recognition Further cell
detection
Species
(M, H, R,
C)
References
c-kit Mast/stem cell
growth factor
receptor
Interstitial cells
of Cajal (ICCs)
M Binder et al., 2015
PDGFRalpha Platelet-de-
rived growth
factor re-
ceptor, alpha
polypeptide
Mesenchymal-
derived cells
M Binder et al., 2015
SMA Smooth mus-
cle actin
Myoﬁbroblasts M, H, R Binder et al., 2015;
Bixby et al., 2002;
Bondurand et al.,
2003; Dettmann
et al., 2014; Hege-
wald et al., 2011;
Hetz et al., 2014;
Kruger et al.,
2002; Metzger
et al., 2009a,
2009b; Suarez-
Rodriguez and
Belkind-Gerson,
2004
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precursor cells.
Some investigators have attempted to enrich putative fetal and
postnatal ENS progenitors using either surface markers such as RET
(Binder et al., 2015; Lo and Anderson, 1995; Natarajan et al., 1999), the
neurotrophin receptor p75(NTR), α4 integrin (Bixby et al., 2002;
Kruger et al., 2002; Mosher et al., 2007; Tsai et al., 2011) or Sox2/
Sox10/Nestin promoter-driven reporter genes (Bondurand et al., 2006;
Heanue and Pachnis, 2011). Using these approaches only some of the
selected cells proliferated and not all proliferating colonies were
equally multipotent. With respect to markers identifying differentia-
tion, unpuriﬁed NLB cultures showed an increasing number of mature
neurons and glia during in vitro culture and after about 2 weeks only
2% of cells remained negative for the pan-neural markers beta-tubulin
III or the glial protein S100beta suggesting that the applied culture
conditions support the in vitro differentiation of neurogenic and
gliogenic progenitors (Binder et al., 2015). Further, qualitative im-
munostainings for neuronal subtypes could be demonstrated, which
include markers for nitric oxide synthase (NOS1), choline acetyl-
transferase (CHAT), vasoactive intestinal polypeptide (VIP), neuro-
peptide Y (NPY), calcitonin gene-related peptide (CALCA or CGRP),
tryptophan hydroxylase (TPH1) and tyrosine hydroxylase (TH); how-
ever especially TPH1þ (serotonergic) and THþ (sympathoadrenal)
neurons tend to decline with increasing age of donor tissue (Table 1;
(Almond et al., 2007; Binder et al., 2015; Bondurand et al., 2003;
Kruger et al., 2002).
5.2. Characterisation of human NLBs
More recently, protocols from rodent studies were adapted for
human neurosphere propagation (Binder et al., 2015; Lindley et al.,
2009; Metzger et al., 2009b; Rauch et al., 2006). As in rodents the
extent of NLB expansion, size and differentiation potential of ENS
precursors was dependent to the donor age. Molecular markers
were adapted from rodent studies assuming similar cell popula-
tions can be identiﬁed. Thus, in primary human NLBs up to one
third of cells were immunoreactive for p75(NTR) and a subfractionPlease cite this article as: Burns, A.J., et al., White paper on guidelines
neuropathies. Dev. Biol. (2016), http://dx.doi.org/10.1016/j.ydbio.2016(not yet quantiﬁed) expressed the putative intracellular/nuclear
progenitor markers Sox2, Sox10, Nestin, BrdU and Ki67 (Binder
et al., 2015; Hetz et al., 2014; Lindley et al., 2009; Metzger et al.,
2009b; Rauch et al., 2006). After multiple cell passages, the pro-
portion of p75þ cells seemed to increase up to 50% in secondary
and 60% in tertiary spheres. Again, as for rodent enteric neural
crest-derived cells all currently applied ‘progenitor’ markers in-
cluding p75 are also present in differentiated human neural cells
making clear discrimination difﬁcult. This is also true for Nestin, a
known intracellular CNS progenitor marker, which was demon-
strated in both neural and non-neural crest-derived cells (Binder
et al., 2015; Rauch et al., 2006). Nevertheless, BrdU-uptake assays
and subsequent co-labeling with TuJ1 and GFAP supports the idea
of a small proliferating neural stem cell pool within the human
spheres that can differentiate into neurons and glia (Metzger et al.,
2009b). Furthermore, postnatal single-cell clonogenic cultures
indicated an overall bipotential frequency of 4% based on TuJ1
and S100 co-immunostainings after 10 days in vitro (Metzger et al.,
2009b). Similar to their rodent counterparts, in vitro generated
human NLBs contained a large fraction of differentiated cells in-
dicated by PGP9.5 and S100 immunostainings (Lindley et al., 2009,
Metzger, 2009a #2055). Whereas the relative PGP9.5 fraction re-
mained constant (50% of total cells), the S100 fraction seemed to
decrease during multiple passages in vitro indicating a neuronal
drift over time. Interestingly, PGP9.5 seems not only to be a pan-
neuronal marker, but appears also in the early enteric neuronal
progenitors (Rauch et al., 2006; Sidebotham et al., 2002). In the
fetal human gut, all cells within premature ganglia are at the same
time PGP9.5 and Nestin-positive, while in the late fetal gut only
developing neurons remain PGP9.5 positive (Rauch et al., 2006). So
far, only one study applied cell sorting strategies to enrich for
human enteric neural (progenitor) cells (Binder et al., 2015). Fol-
lowing ﬂow cytometry to select p75þve human postnatal cells
from submucosal biopsies subsequently generated NLBs contained
almost exclusively neurons and glia (TuJ1 ¼ 74%; S100¼24%), but
no smooth muscle positive cells. After induction of differentiation,
a panel of characteristic neuronal subtype markers could beconcerning enteric nervous system stem cell therapy for enteric
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which included CALCA, NOS1, serotonin, VIP, and CHAT (Metzger
et al., 2009b). As in rodents, colonies from human adult donors
may be more restricted in their differentiation potential, although
there are some discrepancies between different studies depending
on the individual culture conditions and analyses applied (Hagl
et al., 2013a; Metzger et al., 2009a). More than half of the differ-
entiated adult cells were immunoreactive for smooth muscle actin,
about one third stained for either TuJ1 or S100. Interestingly, a
subfraction of differentiated adult neuronal cells seem to express
functional voltage-dependent sodium channels as shown via
patch-clamp electrophysiology (Metzger et al., 2009a).
In summary, little is known about the relationship and between
cells within gut-derived NLB and currently no exclusive stem cell
marker has been identiﬁed. This highlights the need for a battery
of markers and standardized approaches to be used to analyse the
composition of NLBS and NLB-derived differentiated cell entities.
The ability to purify enteric progenitor cells is not only essential
for basic research but particularly for potential cell transplantation
therapies aimed at rescuing or restoring the ENS in various dis-
eases of the gastrointestinal tract.
5.3. What can the ENS ﬁeld learn from the CNS ﬁeld concerning
neurosphere characterization?
Research in both the central and the enteric nervous system
share methodological and biological features, and transferability of
techniques and results might help identify limitations and pro-
blems that the relatively young ENS stem cell community is still
confronted with. One important topic is the acknowledgement of
common operational deﬁnitions, as they are a prerequisite for
scientiﬁc cooperation and technology transfer in the ﬁeld. Current
studies of both CNS and ENS are not able to fully show all the
formal requirements for true stem cells met by neurospheres
(Pastrana et al., 2011). In the CNS ﬁeld, this problem is recognized
by calling neural stem cells (NSCs) “stem-like” or “reporter cells”
(Lee et al., 2010; Park et al., 2006). A similar deﬁnition for ENS
derived NLBs might prevent signiﬁcant confusion. Further, because
no exclusive marker for the isolation of neural stem cells exists, in
the CNS ﬁeld many groups therefore have used combinations of
two or three markers or markers for negative selection (see Pas-
trana et al. (2011)). In future studies, it might be interesting to
prove similar marker proﬁles also in the ENS or to apply broader
age-dependent screening approaches aiming at identiﬁcation of
novel enteric stem cell (surface) marker genes. Interestingly, Par-
ker et al., published a gene-expression proﬁle comparing NSCs
clones (showing clonal self-renewal and clonal multipotentiality)
with those obtained from the neurosphere assay (Parker et al.,
2005). The authors demonstrated that so called “stemness” genes
expressed by both populations differed from a stem-like pattern in
the operationally deﬁned NSCs, towards a more differentiated one
in the cells obtained from the assay. Moreover, it has been shown
that neurosphere-NSCs gene expression is a dynamic process
varying during culture time from a more undifferentiated to a
more differentiated state (Gurok et al., 2004). Thus there is ob-
viously a need for studies going beyond the neurosphere and to
put greater effort towards the identiﬁcation of deﬁnitive markers
with both high speciﬁcity and selectivity.
Finally, to unravel the above mentioned inﬂuence of different
culture conditions and sorting strategies on in vitro stem cell behavior
it might be helpful to analyze enteric neural crest-derived cells using
recently developed transgenic reporter mouse models to track cell
cycle (Abe et al., 2013; Mort et al., 2014), stress responses (Thorp et al.,
2011), chromosomal instability (Balbach and Boiani, 2015) or stem cell
signaling (Ferrer-Vaquer et al., 2010) (Balaskas et al., 2012) in vitro and
in vivo. Furthermore, embryonic development can be simulated inPlease cite this article as: Burns, A.J., et al., White paper on guidelines
neuropathies. Dev. Biol. (2016), http://dx.doi.org/10.1016/j.ydbio.2016vitro using recent (human) pluripotent stem cell technologies to un-
derstand crucial molecular checkpoints for differentiation towards
enteric neural progenitors and fully mature neural cells (Kawaguchi
et al., 2010; Sasselli et al., 2012a). Clearly, much more fundamental
research is needed before we can make signiﬁcant progress towards a
standardized protocol to mark, isolate and harvest enteric progenitors.
The many parallels and previous successes in CNS stem cell research
should encourage ENS researchers to further advance their scientiﬁc
concepts.6. What is the best way to deliver stem cells to the gut?
While the gut is a relatively accessible organ compared to the brain
or spinal cord, delivering cells could be challenging given the size of
the target organ. Moreover, its complex multi-layered organization,
relatively loose connective tissue, and substantial venous and lym-
phatic ﬂow could compromise or facilitate cell engraftment. Optimi-
zation of cell delivery is critically important to maximize cell en-
graftment if we hope to improve gut function, which is the ultimate
goal of ENS stem cell transplantation for enteric neuropathies. To date,
several approaches have been attempted to introduce cells into the
gut wall of laboratory animals: (1) direct injection to the gut wall,
(2) neurosphere implantation, (3) serosal application, (4) in-
traperitoneal injection, and (5) intravascular delivery. These methods
have not yet been systematically investigated to determine which
approach is best. Whatever approach is chosen will need to be mini-
mally invasive, capable of delivering large numbers of donor cells,
allow accurate targeting of cell delivery, and lead to effective cell
spreading throughout the area of disease. In this section, we describe
several delivery methods previously reported in the ﬁeld of ENS cell
therapy research. We also discuss approaches that have been em-
ployed in other areas of regenerative medicine andmay have potential
application in the intestine.
6.1. Injection of cell suspension into the gut wall
6.1.1. Seromuscular approach
Most studies to date have introduced neuronal precursor cells by
laparotomy and direct injection into the gut wall (Anitha et al., 2008;
Dong et al., 2008; Liu et al., 2007, 2013; Micci et al., 2005; Natarajan
et al., 2014). This delivery method allows accurate targeting and per-
mits introduction of large numbers of cells by multiple or large vo-
lume injections. Cells have been suspended at 50,000–400,000 cells
per microliter and microinjected into the gut 2–4 places through
pulled capillary glass needles or metal needles at 2–50 μL per injection
(Anitha et al., 2008; Dong et al., 2008; Liu et al., 2007, 2013; Micci
et al., 2005; Natarajan et al., 2014). Although some investigators have
shown functional recovery of mice with enteric neuropathies follow-
ing cell injection (Anitha et al., 2008; Micci et al., 2005), this method
has several drawbacks. First, there is signiﬁcant leakage of cells
through puncture holes and the ﬁnal location of these cells is not
known. Second, the spreading of cells is poorly controlled, resulting in
a random distribution and poor reproducibility. Finally, suspension of
cells into delivery vehicle, after proteolytic dissociation of neuro-
spheres can predispose to cell death following transplantation. Some
of these drawbacks might be partially overcome by incorporation of
cells into biomaterials such as hydrogels, which polymerize in situ and
enhance retention (Lu et al., 2009), or by co-injectionwith a caspase-1
inhibitor to enhance cell survival (Micci et al., 2005). Despite these
drawbacks, seromuscular cell injection has signiﬁcant potential for
clinical application as it can be used in large animals, including hu-
mans, and is amenable to minimally invasive laparoscopic surgical
techniques which, combined with ultrasound, could allow accurate
targeting into speciﬁc layers of the gut.concerning enteric nervous system stem cell therapy for enteric
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In addition to trans-serosal injection of a cell suspension into
the gut, cells can also be injected through the mucosa via endo-
scopy, a clinically relevant and minimally invasive delivery meth-
od. Endoscopy is a well accepted and commonly used technique in
the diagnosis and treatment of gastrointestinal diseases in clinical
medicine. Cheng and colleagues recently reported the use of co-
lonoscopy to deliver enteric neuronal stem/progenitor cells into
the aganglionic distal colon of mice with Hirschsprung disease
(Cheng et al., 2015). Injection of a cell suspension (50,000 cells in
50 mL volume) was performed under direct visualization and cell
spreading was observed within the submucosal layer extending
circumferentially and for a longitudinal length of 1mm at 1 week
following injection. One disadvantage of this method involves the
technical difﬁculty and the (probably very small) risk of intestinal
perforation during the procedure. However, endoscopic ultra-
sound can be added to facilitate more precise and safe delivery for
future clinical application.
6.2. Implantation of neurospheres into the gut wall
During development, enteric neural crest cells migrate in chains as
they colonise the gut, and the enteric neurons and glia in the mature
gut reside in clusters known as ganglia (Druckenbrod and Epstein,
2005; Faure et al., 2007; Obermayr et al., 2013). These and other data
indicate that enteric neural crest cells and their derivatives require
high cell-cell contact for their survival and migration (Breau et al.,
2006; Hackett-Jones et al., 2011). Generation of neurospheres in vitro
from enteric neural progenitor cells provides a three-dimensional
structure with high cell-cell contact that can be used for transplan-
tation. Previous studies have shown proliferation, extensive migration,
and appropriate neuronal and glial differentiation following trans-
plantation of enteric neurospheres into the distal colon of wild type
mice (Binder et al., 2015; Dettmann et al., 2014; Hotta et al., 2013).
The beneﬁts of neurosphere implantation are demonstrated by the
high rates of cell recovery, subsequent formation of ganglion-like
clusters, and long-term engraftment (3 to 6 months) (Binder et al.,
2015; Dettmann et al., 2014; Hotta et al., 2013). A shortcoming of
neurosphere implantation is that the numbers of cells and the area
they occupy are limited compared to what can be achieved through
injection of a single-cell suspension. Implantation of 2-3 neurospheres
has been described (Hotta et al., 2013), as well as microinjection of
20 neurospheres through a 30 G needle (Dettmann et al., 2014).
Since the size of neurospheres can vary considerably, and each neu-
rosphere may contain only 10,000 cells (Almond et al., 2007), the
small numbers of cells that can be delivered is a technical limitation of
this approach and substantial optimization is needed to make this a
clinically viable strategy.
6.3. Serosal application
A recent study demonstrated the application of human gut-
derived neural progenitor cells in a biodegradable ﬁbrin matrix
onto the serosal surface of mouse intestine that had been chemi-
cally denervated (Hetz et al., 2014). Integration of transplanted
cells occurred in small ganglion structures predominantly located
within the longitudinal muscle layer. The advantages of this ap-
proach are its easy performance and the potential to cover large
areas using the ﬁbrin matrix, which has been approved by FDA and
is available as a spray, referred to as “ﬁbrin glue.” A potential
drawback is that the formation of ﬁbrin via the clotting cascade
may block cell migration out of the matrix. The authors observed
limited penetration of cells through the longitudinal muscle to
reach the myenteric plexus (Hetz et al., 2014). It remains unknown
if the transplanted cells located in the longitudinal muscle will be
able to restore gut function. It is also unclear if injury to the bowelPlease cite this article as: Burns, A.J., et al., White paper on guidelines
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transplanted cells will migrate into and engraft in the bowel.
Chemical injury may alter inﬂammatory mediators or the extra-
cellular matrix as well as other cells in the bowel wall, making it
difﬁcult to know if this approach will work in uninjured tissue.
A number of bioengineering approaches have been used for
delivery for cardiac, retinal and corneal cell replacements (Cutts
et al., 2015; Kundu et al., 2014; Ozcelik et al., 2014). The use of a
natural or synthetic biodegradable matrix, usually as a membrane
seeded with stem/progenitor cells, can provide the appropriate
milieu for cell growth, and when placed directly on the target or
diseased site of an organ (sometimes termed a ‘patch’ or ‘wrap’),
resulting in efﬁcient cell engraftment and homogenous cell dis-
tribution. Replacement of the missing or impaired cell types in
diseased tissue through appropriate engraftment and differentia-
tion of delivered progenitor cells may ultimately restore activity to
the affected tissue. In the ﬁeld of ENS cell therapy, Xu and col-
leagues fabricated biodegradable elastomeric ﬁbrous mesh that
supports proliferation and differentiation of enteric neural crest
cells to form ganglia-like cell clusters without signiﬁcant cell
toxicity (Xu et al., 2013). Enteric neural crest cells grown on this
synthetic membrane could be transplanted to the external muscle
layer of the mouse distal colon in vivo and were found to colonize
the appropriate gut layer 3 weeks following implantation con-
comitant with the degradation of the mesh. Similar to the issue
described above for serosal cell application, it is unclear if cells will
be able to populate the intermuscular layer when the mesh is
applied in vivo on the intestinal serosa. However, serosal pene-
tration was achieved when the mesh was applied to quail embryo
colon in organ culture (Xu et al., 2013). The simplicity of the
‘membrane wrap’ technique for delivering ENS stem cells re-
commends it for further study as it combines ENS stem cell culture
with the application step, and could represent a less invasive and
effective approach to cover the large area of aganglionic gut seen
in HSCR disease.
6.4. Intraperitoneal injection
Rodent p75 and α4 integrin selected neural crest-derived cells
injected intraperitoneally appear to engraft into the postnatal in-
testine of mice with Hirschsprung-like disease (Martucciello et al.,
2007; Tsai et al., 2011). This relatively non-invasive approach could
be done using only local analgesia in the clinical setting. However,
it seems impossible to target the area where the cells are needed.
Tsai et al (2011) observed that intraperitoneally injected enteric
neural crest stem cells preferentially colonized the small intestine
rather than the large intestine (Tsai et al., 2011), suggesting that
colonic aganglionosis is unlikely to be a candidate for this ap-
proach. Interestingly about 10% of the engrafted cells were found
in gut epithelium or lamina propria with most cells in the region of
the myenteric or submucosal plexus. Although transplanted cells
were not observed in liver or kidney three weeks after in-
traperitoneal injection, further evaluation will be required to
guarantee the safety of this approach, as there is the theoretical
potential to form neural crest-derived tumors in other organs.
6.5. Vascular approach
Intravascular cell administration has been described ex-
tensively for cell therapy after myocardial infarction. Numerous
clinical trials have already been conducted for the last three dec-
ades and a recent meta-analysis has reported intracoronary cell
therapy resulted in a moderate improvement of left ventricular
systolic function and a reduction in recurrent myocardial infarc-
tion at 6 months following the intervention (Delewi et al., 2014).
Although there is no published study about intravascularconcerning enteric nervous system stem cell therapy for enteric
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tion, the mesenteric artery could be used to deliver cells to the gut
wall, in contrast to intravenous injection where transplanted cells
would be delivered to all organs. Advantages of this approach in-
clude potentially homogeneous distribution of cells in the diseased
segment of gut if cells are injected into the appropriate feeding
artery. However, previous studies using radiolabeled cells to
evaluate cell distribution following intracoronary delivery re-
vealed only 2–6% of injected cells were retained in the heart at
24 h (Forest et al., 2010; Hofmann et al., 2005). It has been shown
that molecules that guide immune cell trafﬁcking after brain in-
jury stimulate homing of neural stem cells into brain parenchyma
after intravascular delivery (Pluchino et al., 2003). However, it is
unknown if ENS stem cells can home like immune cells, and
whether the necessary chemotactic factors are available in the
aganglionic gut environment in people with Hirschsprung disease.7. How do we measure cell transplantation success?
Ultimately, the “successful” transplantation of stem cells/pro-
genitors will be deﬁned by the ability of these cells to improve gut
function. The most critical functional improvements are deﬁned in
points A1–5 below. In points B1–8 we also deﬁne a series of ana-
tomic and neurochemical analyses that will determine the degree
to which the transplanted cells integrate into the bowel and mimic
the normal ENS, but restoration of function may not require re-
storation of normal anatomy or a normal complement of neurons.
In human patients, functional studies are probably the only viable
assessment of transplant success.
7.1. Animal models
(A) Functional assays and survival. The following assays provide
evidence that transplanted cells have generated functional neu-
rons, improved gut function and exhibit long-term survival:
1. Ex vivo studies to show that graft-derived neurons are electrically
active (can ﬁre action potentials) and receive inputs. This is im-
portant as developing enteric neurons (Hao et al., 2012) and
adult neural stem cells (Moe et al., 2005) can express neuronal
markers without being electrically active. These assays could be
performed using a variety of electrophysiological and functional
imaging approaches including sharp electrode intracellular
recordings, patch clamping (Hao et al., 2012), calcium (Hao
et al., 2011) or voltage-sensitive imaging.
2. Ex vivo studies to show that graft-derived neurons functionally
innervate the muscle. Functional integration can be demon-
strated by stimulation of graft-derived neurons using optoge-
netics or electrical ﬁeld stimulation (if there are no non-graft-
derived neurons in the vicinity). Stimulation of graft-derived
neurons should result in (a) contraction and/or relaxation of the
circular muscle as assessed by contractility studies in organ bath
experiments or spatiotemporal mapping, and/or (b) the pre-
sence of excitatory junction potentials (EJPs) and inhibitory
junction potentials (IJPs), the electrical events underlying con-
tractions and relaxations respectively, in electrophysiological
studies in opened preparations of recipient gut.
3. Ex vivo studies to show that graft-derived neurons establish or
contribute to circuitry for mediating complex motility patterns
appropriate for the gut region. Gastrointestinal motility patterns
are region-speciﬁc. For example, mixing and emptying in the
stomach, mixing and propulsion in the small intestine, and
propulsion in the colon are distinct patterns of contraction and
relaxation necessary for proper bowel function. Analysis of bo-
wel motor function after transplantation could be performedPlease cite this article as: Burns, A.J., et al., White paper on guidelines
neuropathies. Dev. Biol. (2016), http://dx.doi.org/10.1016/j.ydbio.2016using spatiotemporal mapping, calcium imaging, or simulta-
neous tension recordings from multiple sites.
4. In vivo studies to show that when transplanted into animal models
of human disease, appropriate function is improved. For example,
following transplantation into the colon of a HSCR animal
model, propulsive gut motility (including coordinated contrac-
tion and relaxation) would occur in the previously aganglionic,
tonically contracted region. Depending on the disease model,
“gut motility” might be assessed by measuring total GI transit
(e.g. carmine dye administered by gavage (Sasselli et al., 2013)),
gastric emptying (e.g. using rhodamine B dextran), small intes-
tine transit (e.g. using rhodamine B dextran), time to expel a
glass bead inserted into the rectum, pellet counting, esophageal
manometry, anorectal manometry, or gavage of barium contrast
and then X-ray imaging of anaesthetized animals to determine
rate of propulsion and to quantify contractile activity (Der-Si-
laphet et al., 1998). Following transplantation into a HSCR
animal model, post-mortem examination could also determine
whether there is a megacolon. A study of Ednrb-/- mice, a mouse
model of HSCR, suggested that the intestinal microbiome plays
a role in the development of Hirschsprung-associated entero-
colitis (HAEC) (Pierre et al., 2014). Hence, investigations of the
microbial proﬁle of recipient animals to determine if there is a
restoration of “normal” microbial proﬁle would also be
informative.
5. Long-term survival of graft-derived cells (at least 6 months). It
would be valuable to demonstrate that transplanted cells sur-
vive in the bowel wall. While the ideal human therapy should
provide beneﬁt for decades, at least 6 months of cell survival
and improved function in animal models is an achievable and
valuable endpoint.
(B) Structural, neurochemical, neurogenesis and survival as-
says: the following assays will provide evidence that transplanted
cells have generated an ENS that is similar to that generated dur-
ing normal development:
1. Migration of transplanted cells away from transplant site and co-
lonization of normal gut locations (myenteric and submucosal
regions), but not ectopic locations. Ectopic locations to be ex-
amined should include adrenal glands, lumbar sympathetic ganglia
(common primary and secondary sites of neuroblastoma, a tumour
of neural crest-derived cells), other abdominal organs and lymph
nodes. These experiments require that the transplanted stem/pro-
genitors express genetic markers distinct from the recipient.
2. Expression of pan-neuronal and glial markers by transplanted
cells. Pan-neuronal markers should include PGP9.5, HuC/D,
neuron-speciﬁc enolase (NSE) and Tuj1, while glial markers
should include GFAP, S100β and Sox10 (Hotta et al., 2013).
3. Formation of, or contribution to, ganglia (clusters of neurons and
glia) by graft-derived neurons that are similar in size to en-
dogenous ganglia in the relevant gut region.
4. Expression of enteric neuron subtype markers, and in similar
proportions to the normal ENS in that gut region. In all mam-
malian species that have been examined to date, excitatory
motor neurons are cholinergic (express the synthetic enzyme,
choline acetyltransferase, ChAT, and the vesicular acetylcholine
transporter, VAChT) and also contain tachykinins such as sub-
stance P, while inhibitory motor neurons express neuronal nitric
oxide synthase (nNOS) and vasoactive intestinal peptide (VIP).
Markers of intrinsic sensory neurons and some populations of
enteric interneurons vary between species, but could also be
examined.
5. Absence of markers of inappropriate non-neuronal lineages (e.g.
markers of osteogenesis, melanocytes, cartilage, adrenal me-
dulla, smooth muscle, adipocytes, interstitial cells of Cajal (ICC),concerning enteric nervous system stem cell therapy for enteric
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Brn3.0, which is expressed by neural crest-derived dorsal root
ganglion neurons).
6. Incorporation of S-phase markers such as EDU or BrdU by graft-
derived neurons after transplantation of stem/progenitor cells
would show that neurons have been generated after trans-
plantation. However, it is possible that function could be re-
stored simply by transplanting neuronal precursors or neurons
(Hotta et al., 2013).
7. Projection of axons of graft-derived neurons to normal sites (cir-
cular muscle, other ganglia, mucosa), and expression of appro-
priate neurotransmitter synthetic enzymes within varicosities
(see point #4 above) and expression of synaptic proteins (see
point #8 below).
8. Electron microscopy, high resolution confocal microscopy or super-
resolution microscopy studies to show that the axons of graft-de-
rived neurons form synapses or close appositions with other neu-
rons, glia, PDGFR-αþ ﬁbroblasts, ICC and circular muscle cells.
Ultrastructural studies will require pre- or post-embedding
immunolabeling to identify speciﬁcally axons of graft-derived
neurons (for example, use of antisera to GFP if the transplanted
cells express GFP). For non-ultrastructural studies, expression of
closely apposed pre-synaptic (e.g. SNAP25, synaptotagmin, sy-
naptophysin, synaptobrevin, neurexin, syntaxin) and post-sy-
naptic (e.g. PSD95, neuroligin) proteins would provide support
for the presence of synapses.
7.2. Human patients with enteric neuropathies
In patients into whom progenitors have been transplanted into
the bowel, changes in patients’ Quality of Life scores should be
assessed, if possible. The following tests would indicate restoration
of function:
1. HSCR infants: Improved passage of bowel movements without
abdominal distension, bilious emesis, growth failure or en-
terocolitis. Studies to determine whether there is a restoration of
“normal” microbial proﬁle in the stool would also be informative.
2. Adults (and children) with esophageal achalasia: Improved
swallowing without retained ﬂuid or food in the esophagus.
Esophagus function can be assessed using swallow tests with
radio-opaque contrast and with 3D high-resolution oesophageal
manometry, particularly focusing upon the gastro-oesophageal
junction. Esophageal pH and impedance monitoring would also
be useful to assess the frequency of gastroesophageal reﬂux
after cell transplantation.
3. Adults with gastroparesis caused by defective enteric neurons;
gastric emptying studies or antro-duodenal manometry are
valuable ways to assess gastric function.8. How can cell safety be assessed?
Much current work addressing the possibility of stem cell therapy
for HSCR and other intestinal motility disorders has focused on the use
of enteric neural progenitor cells harvested from the gut itself. Al-
though this approach offers the possibility of autologous therapy, most
current methods involve signiﬁcant periods of ex vivo culture during
which there is the potential for the appearance of genetic variants. So
far, there has been little consideration of possible safety issues beyond
assessing the spread of transplanted cells outside the gut and limited
studies of tumor formation. With the need to perform detailed quality
control for each patient, the costs for such autologous transplants are
potentially high. On the other hand, human Pluripotent Stem Cells
(hPSC), whether embryonic stem (ES) cells, or induced pluripotent
stem (iPS) cells, present a versatile source of different cell types forPlease cite this article as: Burns, A.J., et al., White paper on guidelines
neuropathies. Dev. Biol. (2016), http://dx.doi.org/10.1016/j.ydbio.2016transplantation in diverse regenerative medicine applications, and the
possible safety issues associated with the acquisition of genetic or
epigenetic changes is under active consideration (Goldring et al., 2011).
hPSC are currently being tested in a number of clinical trials in
which hPSC-derived retinal pigment cells are being transplanted
to treat age related macular degeneration. Other conditions for
which progress is being made towards clinical trials include Par-
kinson’s disease, Huntington’s disease, type 1 diabetes and spinal
cord injury. The potential of hPSC for producing enteric neurons
for the treatment of Hirschsprung disease is now apparent with
the development of protocols for producing neural crest cells
(Menendez et al., 2011), the precursors of enteric neurons. Since
hPSC can be maintained and expanded indeﬁnitely, they offer
distinct advantages over somatic stem cells in terms of the scale
and reproducibility with which derivative cells can be produced. A
single established hPSC line could, in principle, be used to provide
cells for treating many hundreds or thousands of patients, whereas
for somatic cells multiple isolates would most likely be required.
On the other hand, autologous transplants would avoid immune
rejection and the need for immunosuppressive therapy. The use of
iPS technology is appealing in this context. More insidious, how-
ever, is the propensity of pluripotent stem cells to acquire genetic
and epigenetic changes upon long-term culture and expansion
(Baker et al., 2007; Draper et al., 2004; International Stem Cell
et al., 2011). Such changes may reduce the efﬁcacy of generating
speciﬁc derivative cell types, or could potentially compromise
safety, for example promoting tumour growth.
Although early passages of newly derived human ES cells ty-
pically exhibit a normal diploid karyotype, on prolonged passage
they may acquire non-random changes to their chromosome
constitution. The most common changes seen are gains of chro-
mosome 1, 12, 17, or 20, either as extra copies of the whole chro-
mosome, or as translocated fragments, although tandem duplica-
tions also occur (Baker et al., 2007; Draper et al., 2004; Nguyen
et al., 2014; Taapken et al., 2011). It is also notable that gains of the
long arm of chromosome 17 and the short arm of chromosome 12
are frequent in embryonal carcinoma cells, the malignant coun-
terparts of ES cells and the stem cells of germ cell tumours. Human
iPS cells are likewise prone to gains of the same chromosomal
regions as ES cells (Taapken et al., 2011), and these observations
were conﬁrmed in a comparative study by The International Stem
Cell Initiative (ISCI) of the genotypes of cells from early and late
passages of 122 human ES and iPS cells, as well as from surveying
literature reports (International Stem Cell et al., 2011). In addition,
the ISCI study recorded examples of repetitive genomic losses af-
fecting regions of chromosomes 10, 18 and 22. Occasional kar-
yotypic changes affecting almost all other chromosomes have also
been reported, but the changes are sporadic and form no dis-
cernible pattern, although it is notable that changes affecting
chromosome 4 have almost never been reported.
The frequency of the commonly observed changes suggests
that these genetic changes offer cells a selective growth advantage.
This was conﬁrmed by trials in which cultures of diploid hPSC
were spiked with a small proportion of karyotypically abnormal
cellsthat then took over the cultures within a very few passages
(Olariu et al., 2010). In the case of chromosome 20 gains it has
been possible to identify a gene, BCL2L1, that appears to drive the
selective advantage by limiting apoptosis of hPSC during passaging
(Avery et al., 2013; Nguyen et al., 2014). This gene lies in a short
region of chromosome 20 that is subject to frequent ampliﬁcation
but often too short to be detected by standard G-banding kar-
yotyping. It can be detected by ﬂuorescence in situ hybridization
(FISH) with appropriate probes, or by SNP or CGH array hy-
bridization. Frequent screening of hPSC lines by these techniques
is warranted, as the amplicon is often present in otherwise kar-
yotypically diploid cells – in the ISCI study, the amplicon wasconcerning enteric nervous system stem cell therapy for enteric
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karyotypically diploid. These high-resolution techniques may also
reveal copy number variations (CNVs), small regions of genomic
gain or loss, or rearrangement elsewhere in the genome, but their
signiﬁcance remains unclear. Some CNVs have been identiﬁed on
chromosomes 12 and 17, but repeated gains at speciﬁc loci are
elusive, and some certainly reﬂect variants normally observed in
the human population (International Stem Cell et al., 2011; Laurent
et al., 2011). The failure to identify commonly affected genes, apart
from BCL2L1 on chromosome 20, does raise a question about the
simple hypothesis that, in general, the selective advantage pro-
vided by speciﬁc chromosomal gain, or loss, may be attributed to
the altered expression of a single gene. It may be that more
complex mechanisms must be sought.
Epigenetic changes also occur in hPSC, but repetitive changes
are not well documented. In the ISCI study, extensive changes in
the DNA methylation of many genes were noted but no pattern
emerged that was consistent across cell lines (International Stem
Cell et al., 2011). Changes in the expression of some imprinted
genes suggested erasure of imprinting, but it has also been re-
ported that the imprinted genes of human ES cells are relatively
stable in comparison to those of mouse ES cells (Rugg-Gunn et al.,
2005). Perhaps the most widely observed epigenetic change in
hPSC is the loss of X-inactivation. While the presence of two active
X chromosomes may indicate of a primitive or naïve state for
hPSC, many female hPSC appear to have an inactive X chromo-
some (International Stem Cell et al., 2007). In some cases, this
inactive X seems to be re-activated (Enver et al., 2005) in a way
that is permanent and non-physiological, a phenomenon that has
been called erosion of inactivation (Mekhoubad et al., 2012).
Although these observations of genetic and epigenetic in-
stability do raise safety concerns about the use of hPSC derivatives
for regenerative medicine, their real signiﬁcance remains unclear.
Much discussion has focused on the danger of the formation of
teratocarcinomas, in which undifferentiated stem cells with ma-
lignant potential persist. However, in any likely treatment it will
be speciﬁc differentiated derivatives or their progenitors, not the
undifferentiated stem cells that will be transplanted. So it is the
potential effects that genetic changes will have on the behaviour of
the differentiated cells that must be considered, (Goldring et al.,
2011). On the precautionary principle, hPSC lines with overt kar-
yotypic changes should not be transplanted to patients. However,
as higher resolution screening techniques are used, genetic var-
iants will almost inevitably be uncovered in all cell lines to the
extent that the terms ‘normal’ and ‘abnormal’ lose their meaning:
not only do variants that are detected in cultured hPSC occur in
healthy humans (International Stem Cell et al., 2011) but normal
tissues within individuals may also harbor karyotypically variant
cells, although their signiﬁcance is unclear (Knouse et al., 2014).
Further, the ability of screening techniques to detect variant cells
in a population is limited, so that cultures scored as lacking spe-
ciﬁc chromosomal variants may nevertheless harbor small un-
detected populations of variant cells.
The future development of hPSC for regenerative medicine will
require the assessment of the effects of speciﬁc genetic changes
that arise in undifferentiated hPSC on the function and behaviour
of the derivative cells required for a particular application, such as
for Hirschsprung disease treatment. It is also worth considering
that some variants might themselves provide advantages for re-
generative medicine. For example, the anti-apoptotic effects of
BCL2L1 might enhance the engraftment of cells that carry the
chromosome 20 amplicon. In any case, it is likely that the con-
sequences of particular variations will vary between applications
and so will require assessment on a case by case basis. Although
genetic variation in hPSC is common, it is noteworthy that in the
ISCI study 79 out of 120 lines studied in early and late passagePlease cite this article as: Burns, A.J., et al., White paper on guidelines
neuropathies. Dev. Biol. (2016), http://dx.doi.org/10.1016/j.ydbio.2016retained a normal karyotype throughout and the recurrent ab-
normalities, whether cytogenetic or CNV, were detected in less
than 50% of the cell lines. Such changes also occur in murine ES
cells, but these cells have long been used successfully for the
production of germ line chimeras and viable transgenic mice.
Therefore there is every reason to expect that if hPSC for human
clinical applications are properly monitored and the consequences
of speciﬁc variants assessed, it will be possible to use these cells
safely for regenerative medicine. Less is known currently about the
extent to which these safety issues also apply to autologous adult
stem cells, though if these require less ex vivo culture, the risks for
adverse genetic change may be less than for long term cultured
hPSC. However, that advantage is tempered by the greater difﬁ-
culties of access and standardization.
Looking further towards clinical application of cell therapy for
enteric neuropathies it is clear that rigorous standards, in both the
generation and application of any cellular therapeutic, are required
to ensure core standardization of treatment across multiple cen-
ters, at the local, national and international level. Addressing the
challenges set out above will allow for development of efﬁcient
protocols for the sourcing of stem cells, their expansion, the
method of transplantation and analysis of successful outcomes in
patients via clinical trails. However, standardization and compar-
ability at each step is critical, not only for safety but to enable
comparison between techniques. Ultimately, it will be important
that any treatment with cellular products be standardized across
centers to allow for approval by the various national regulatory
bodies in terms of quality, safety and efﬁcacy. Considerable inter-
action between the ﬁeld and these regulatory bodies will be re-
quired to determine speciﬁcation and quality standards, together
with providing clear evidence of consistency across processes.9. Conclusions: the prospect of human trials
As documented across all of the sections above, the last decade
has yielded signiﬁcant progress in the ﬁeld of enteric neural stem
cells for therapy. Not only have we witnessed the development of
robust and reproducible methodologies to facilitate the harvesting
and propagation of therapeutic cells, their potential and safety is
being tested in the context of established models of disease. More
importantly, there is now a critical mass of researchers addressing
the many challenges that remain and validating emerging tech-
niques and ﬁndings. This, for the ﬁrst time, has brought into view a
real prospect of clinical application and ‘ﬁrst in man trials’.
What would such trials look like? Although reﬁnement is clearly
needed, the harvesting of human-derived enteric neural cells for
transplantation has already been established by a number of groups.
Adaptation of protocols to satisfy national and international regulatory
bodies and the development of approved clinical grade ‘medicines’
should not prove a major problem as a number of stem cell therapies
are already established in clinical practice. Initial trials of cells de-
signed for therapy of enteric neuropathies may be best instituted into
non-diseased intestine of ‘volunteers’ with terminal diseases such as
cancers not affecting the transplanted intestine, or into paediatric
patients whose disease is severe and currently available interventions
such as surgery offer no real prospect of improvement or are deemed
to carry excessive risk. In the former, the recipient intestine is likely to
be harvested at a future timepoint to facilitate assessment of cell
viability, spread, functional integration and safety. In the latter, func-
tional improvement would provide the outcome measure but ethical
consideration would need to be given to the trial of such therapies in
the context of increasingly safe life sustaining interventions such as
parenteral nutrition and improving reported outcomes of intestinal
transplantation. The gut is a huge immune organ and immunological
rejection will no doubt provide an obstacle to cell transplantation.concerning enteric nervous system stem cell therapy for enteric
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of grafts but perhaps a more attractive solution would be the use of
autologous transplantation. The validation of harvesting cells by
endoscopy would favour this strategy allowing also for the delivery
of therapeutic cells into diseased segments of bowel. Inherent cell
dysfunction of cells harvested from affected bowel may limit this
application unless transplanted cells retain sufﬁcient function or
can be delivered in large numbers or genetic rescue is feasible. Even
if restoration of genetic normality is not possible some form of
cellular manipulation is likely to be required to direct appropriate
differentiation and engraftment of cells. Arguably the biggest
challenge before contemplation of trials in man is the need for deep
characterization of human enteric neuropathies. Many of these
conditions remain poorly deﬁned. Only then can one realize the
precise requirements to be addressed by the transplanted ther-
apeutic neural stem cells.
Accepting that the coming years will need to address and over-
come a number of key challenges the combined efforts of a con-
sortium bring the dream of curative therapies for enteric neuropathies
closer to reality.Acknowledgements
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